EP1045843A1 - Inhibitors of farnesyl-protein transferase - Google Patents
Inhibitors of farnesyl-protein transferaseInfo
- Publication number
- EP1045843A1 EP1045843A1 EP98960545A EP98960545A EP1045843A1 EP 1045843 A1 EP1045843 A1 EP 1045843A1 EP 98960545 A EP98960545 A EP 98960545A EP 98960545 A EP98960545 A EP 98960545A EP 1045843 A1 EP1045843 A1 EP 1045843A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- aryl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000004357 Transferases Human genes 0.000 title claims abstract description 65
- 108090000992 Transferases Proteins 0.000 title claims abstract description 65
- 239000003112 inhibitor Substances 0.000 title description 29
- 150000001875 compounds Chemical class 0.000 claims abstract description 212
- 238000000034 method Methods 0.000 claims abstract description 76
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 35
- 125000000623 heterocyclic group Chemical group 0.000 claims description 227
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 212
- 239000001257 hydrogen Substances 0.000 claims description 198
- 229910052739 hydrogen Inorganic materials 0.000 claims description 198
- 125000003118 aryl group Chemical group 0.000 claims description 167
- 150000002431 hydrogen Chemical class 0.000 claims description 154
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 128
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 115
- 125000003107 substituted aryl group Chemical group 0.000 claims description 95
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 84
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 82
- UWYZHKAOTLEWKK-UHFFFAOYSA-N tetrahydro-isoquinoline Natural products C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 72
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 63
- 229910052736 halogen Inorganic materials 0.000 claims description 59
- 150000002367 halogens Chemical class 0.000 claims description 59
- 229910052731 fluorine Inorganic materials 0.000 claims description 53
- 229910052801 chlorine Inorganic materials 0.000 claims description 51
- 150000003839 salts Chemical class 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 49
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 44
- 125000001424 substituent group Chemical group 0.000 claims description 40
- 230000003287 optical effect Effects 0.000 claims description 39
- 102200029256 rs121964925 Human genes 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 33
- -1 C 1 -C6 alkyl Chemical group 0.000 claims description 30
- 150000002460 imidazoles Chemical class 0.000 claims description 29
- 229910052794 bromium Inorganic materials 0.000 claims description 27
- 125000002883 imidazolyl group Chemical group 0.000 claims description 27
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 25
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 125000003342 alkenyl group Chemical group 0.000 claims description 17
- 125000004076 pyridyl group Chemical group 0.000 claims description 17
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 125000001041 indolyl group Chemical group 0.000 claims description 16
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 16
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 16
- 125000000335 thiazolyl group Chemical group 0.000 claims description 16
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 125000001544 thienyl group Chemical group 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 125000001425 triazolyl group Chemical group 0.000 claims description 10
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 8
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 8
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 7
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 102220092886 rs143733205 Human genes 0.000 claims description 6
- 125000005336 allyloxy group Chemical group 0.000 claims description 4
- 125000003435 aroyl group Chemical group 0.000 claims description 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 4
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 4
- XLKWINMODLDXOJ-UHFFFAOYSA-N 4-[[5-(1h-benzimidazol-2-ylmethyl)imidazol-1-yl]methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CN1C(CC=2NC3=CC=CC=C3N=2)=CN=C1 XLKWINMODLDXOJ-UHFFFAOYSA-N 0.000 claims description 3
- WYDYTCHHWWAZRC-UHFFFAOYSA-N 4-[[5-[(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound C1C=2C=C(OC)C(OC)=CC=2CCN1CC1=CN=CN1CC1=CC=C(C#N)C=C1 WYDYTCHHWWAZRC-UHFFFAOYSA-N 0.000 claims description 3
- 108010085793 Neurofibromin 1 Proteins 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- SKVKXDSUWSGDDX-NDEPHWFRSA-N (3s)-n-[(3-chlorophenyl)methyl]-2-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]-3,4-dihydro-1h-isoquinoline-3-carboxamide Chemical compound ClC1=CC=CC(CNC(=O)[C@H]2N(CC3=CC=CC=C3C2)CC=2N(C=NC=2)CC=2C=CC(=CC=2)C#N)=C1 SKVKXDSUWSGDDX-NDEPHWFRSA-N 0.000 claims description 2
- 201000004569 Blindness Diseases 0.000 claims description 2
- 208000005331 Hepatitis D Diseases 0.000 claims description 2
- 208000037262 Hepatitis delta Diseases 0.000 claims description 2
- 208000029570 hepatitis D virus infection Diseases 0.000 claims description 2
- MZEMLHRQHUKCJD-UHFFFAOYSA-N n-[2-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]-3,4-dihydro-1h-isoquinolin-7-yl]acetamide Chemical compound C1C2=CC(NC(=O)C)=CC=C2CCN1CC1=CN=CN1CC1=CC=C(C#N)C=C1 MZEMLHRQHUKCJD-UHFFFAOYSA-N 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 230000004276 retinal vascularization Effects 0.000 claims description 2
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
- RVAGEYGRHKGODE-UHFFFAOYSA-N 4-[[5-[[4-(3-bromophenyl)-4,5,6,7-tetrahydroimidazo[4,5-c]pyridin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound BrC1=CC=CC(C2C3=C(N(C=N3)CC=3N(C=NC=3)CC=3C=CC(=CC=3)C#N)CCN2)=C1 RVAGEYGRHKGODE-UHFFFAOYSA-N 0.000 claims 1
- FBKUQUHPFYAYIP-UHFFFAOYSA-N BrC=1C=C2CCN(C(C2=CC1)=O)CC1=CN=CN1CC1=CC=C(C=C1)C#N.CC1=C(C=CC=C1)C1=C2C=CN(C2=CC=C1)CC1=CN=CN1CC1=CC=C(C=C1)C#N Chemical compound BrC=1C=C2CCN(C(C2=CC1)=O)CC1=CN=CN1CC1=CC=C(C=C1)C#N.CC1=C(C=CC=C1)C1=C2C=CN(C2=CC=C1)CC1=CN=CN1CC1=CC=C(C=C1)C#N FBKUQUHPFYAYIP-UHFFFAOYSA-N 0.000 claims 1
- 102000007530 Neurofibromin 1 Human genes 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 abstract description 5
- 102000043276 Oncogene Human genes 0.000 abstract description 4
- 230000006126 farnesylation Effects 0.000 abstract 2
- UITKQZZSZUEHEA-NYHFZMIOSA-N 2,2,2-trifluoro-n-[(1r,2s)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-phenylpropan-2-yl]acetamide Chemical compound O([C@@H]([C@@H](NC(=O)C(F)(F)F)C)C=1C=CC=CC=1)C(C=C1C=N2)=CC=C1N2C1=CC=C(F)C=C1 UITKQZZSZUEHEA-NYHFZMIOSA-N 0.000 description 109
- 238000002360 preparation method Methods 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 59
- 239000007787 solid Substances 0.000 description 55
- 239000000243 solution Substances 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 45
- 238000004458 analytical method Methods 0.000 description 44
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 108010014186 ras Proteins Proteins 0.000 description 33
- 229910001868 water Inorganic materials 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 32
- 238000003556 assay Methods 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 28
- 102000016914 ras Proteins Human genes 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000012267 brine Substances 0.000 description 25
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
- 239000000047 product Substances 0.000 description 23
- 239000002904 solvent Substances 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 20
- 239000000543 intermediate Substances 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 239000000758 substrate Substances 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 239000003921 oil Substances 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 238000000746 purification Methods 0.000 description 12
- 238000010265 fast atom bombardment Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 229940125436 dual inhibitor Drugs 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 125000002950 monocyclic group Chemical group 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 108091081021 Sense strand Proteins 0.000 description 8
- 150000001299 aldehydes Chemical class 0.000 description 8
- 239000013613 expression plasmid Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 7
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- MFQQFAGIVRNQCT-UHFFFAOYSA-N 4-[[5-[(4-bromoindol-1-yl)methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound C1=CC=2C(Br)=CC=CC=2N1CC1=CN=CN1CC1=CC=C(C#N)C=C1 MFQQFAGIVRNQCT-UHFFFAOYSA-N 0.000 description 5
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 108010050749 geranylgeranyltransferase type-I Proteins 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 108700042226 ras Genes Proteins 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102100039788 GTPase NRas Human genes 0.000 description 4
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 150000004985 diamines Chemical class 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- 230000013823 prenylation Effects 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000005932 reductive alkylation reaction Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003558 transferase inhibitor Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000009966 trimming Methods 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 description 2
- BJFPYGGTDAYECS-UHFFFAOYSA-N (3-chlorophenyl)methanamine Chemical compound NCC1=CC=CC(Cl)=C1 BJFPYGGTDAYECS-UHFFFAOYSA-N 0.000 description 2
- HFPVZPNLMJDJFB-LBPRGKRZSA-N (3s)-2-[(2-methylpropan-2-yl)oxycarbonyl]-3,4-dihydro-1h-isoquinoline-3-carboxylic acid Chemical compound C1=CC=C2C[C@@H](C(O)=O)N(C(=O)OC(C)(C)C)CC2=C1 HFPVZPNLMJDJFB-LBPRGKRZSA-N 0.000 description 2
- NDNUEXODBBSVPU-UHFFFAOYSA-N (7-bromo-3,4-dihydro-1h-isoquinolin-2-yl) 2,2,2-trifluoroacetate Chemical compound C1=C(Br)C=C2CN(OC(=O)C(F)(F)F)CCC2=C1 NDNUEXODBBSVPU-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- KKAJNETZQAWWBK-UHFFFAOYSA-N 4-[[5-(indol-1-ylmethyl)imidazol-1-yl]methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CN1C(CN2C3=CC=CC=C3C=C2)=CN=C1 KKAJNETZQAWWBK-UHFFFAOYSA-N 0.000 description 2
- IAMZOIFUAWXKFE-UHFFFAOYSA-N 4-[[5-[(7-bromo-3,4-dihydro-1h-isoquinolin-2-yl)methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound C1C2=CC(Br)=CC=C2CCN1CC1=CN=CN1CC1=CC=C(C#N)C=C1 IAMZOIFUAWXKFE-UHFFFAOYSA-N 0.000 description 2
- ULIWECVOQCGUAS-UHFFFAOYSA-N 4-[[5-[(7-phenyl-3,4-dihydro-1h-isoquinolin-2-yl)methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CN1C(CN2CC3=CC(=CC=C3CC2)C=2C=CC=CC=2)=CN=C1 ULIWECVOQCGUAS-UHFFFAOYSA-N 0.000 description 2
- YCYCSDRSPZPPEL-UHFFFAOYSA-N 4-[[5-[[5-(2,4-dichlorophenyl)-3,4-dihydro-1h-isoquinolin-2-yl]methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound ClC1=CC(Cl)=CC=C1C1=CC=CC2=C1CCN(CC=1N(C=NC=1)CC=1C=CC(=CC=1)C#N)C2 YCYCSDRSPZPPEL-UHFFFAOYSA-N 0.000 description 2
- GRJZJFUBQYULKL-UHFFFAOYSA-N 4-bromo-1h-indole Chemical compound BrC1=CC=CC2=C1C=CN2 GRJZJFUBQYULKL-UHFFFAOYSA-N 0.000 description 2
- LCTDIQQSJICLJM-UHFFFAOYSA-N 4-phenyl-1h-indole Chemical compound C1=CC=C2NC=CC2=C1C1=CC=CC=C1 LCTDIQQSJICLJM-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108010006731 Dimethylallyltranstransferase Proteins 0.000 description 2
- 102000005454 Dimethylallyltranstransferase Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- VWFJDQUYCIWHTN-FBXUGWQNSA-N Farnesyl diphosphate Natural products CC(C)=CCC\C(C)=C/CC\C(C)=C/COP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-FBXUGWQNSA-N 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 101710091881 GTPase HRas Proteins 0.000 description 2
- 102100029974 GTPase HRas Human genes 0.000 description 2
- 108091006109 GTPases Proteins 0.000 description 2
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 102100026379 Neurofibromin Human genes 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 2
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 2
- 125000004597 dihydrobenzothiopyranyl group Chemical group S1C(CCC2=C1C=CC=C2)* 0.000 description 2
- WOKPSXJEBSRSAT-UHFFFAOYSA-N dihydrobenzothiopyranyl sulfone group Chemical group S1C(CCC2=C1C=CC=C2)S(=O)(=O)C2SC1=C(CC2)C=CC=C1 WOKPSXJEBSRSAT-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 108091005640 farnesylated proteins Proteins 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- OINNEUNVOZHBOX-KGODAQDXSA-N geranylgeranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C\CC\C(C)=C\CO[P@@](O)(=O)OP(O)(O)=O OINNEUNVOZHBOX-KGODAQDXSA-N 0.000 description 2
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 150000004693 imidazolium salts Chemical class 0.000 description 2
- 239000012742 immunoprecipitation (IP) buffer Substances 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- YSHPSUHENLCWLM-UHFFFAOYSA-N methyl 2-(1-tritylimidazol-4-yl)acetate Chemical compound C1=NC(CC(=O)OC)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 YSHPSUHENLCWLM-UHFFFAOYSA-N 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 102220002645 rs104894309 Human genes 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- LCZVKKUAUWQDPX-UHFFFAOYSA-N tert-butyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]ethyl]amino]acetate Chemical compound CC(=O)OC1=CC=CC=C1CN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC1=CC=CC=C1OC(C)=O LCZVKKUAUWQDPX-UHFFFAOYSA-N 0.000 description 2
- PWPKRLMPHNRWHK-UHFFFAOYSA-N tert-butyl 7-bromo-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1=C(Br)C=C2CN(C(=O)OC(C)(C)C)CCC2=C1 PWPKRLMPHNRWHK-UHFFFAOYSA-N 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000004589 thienofuryl group Chemical group O1C(=CC2=C1C=CS2)* 0.000 description 2
- 125000004587 thienothienyl group Chemical group S1C(=CC2=C1C=CS2)* 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- QNEGDGPAXKYZHZ-UHFFFAOYSA-N (2,4-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1Cl QNEGDGPAXKYZHZ-UHFFFAOYSA-N 0.000 description 1
- HFPVZPNLMJDJFB-GFCCVEGCSA-N (3r)-2-[(2-methylpropan-2-yl)oxycarbonyl]-3,4-dihydro-1h-isoquinoline-3-carboxylic acid Chemical compound C1=CC=C2C[C@H](C(O)=O)N(C(=O)OC(C)(C)C)CC2=C1 HFPVZPNLMJDJFB-GFCCVEGCSA-N 0.000 description 1
- QIJRJXBIUBUJHH-UMSFTDKQSA-N (3s)-n-[(3-chlorophenyl)methyl]-2-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]-7-phenyl-3,4-dihydro-1h-isoquinoline-3-carboxamide Chemical compound ClC1=CC=CC(CNC(=O)[C@H]2N(CC3=CC(=CC=C3C2)C=2C=CC=CC=2)CC=2N(C=NC=2)CC=2C=CC(=CC=2)C#N)=C1 QIJRJXBIUBUJHH-UMSFTDKQSA-N 0.000 description 1
- ZLPVOYVTUMYIMV-UHFFFAOYSA-N (7-amino-3,4-dihydro-1h-isoquinolin-2-yl) 2,2,2-trifluoroacetate Chemical compound C1CN(OC(=O)C(F)(F)F)CC2=CC(N)=CC=C21 ZLPVOYVTUMYIMV-UHFFFAOYSA-N 0.000 description 1
- OCQJSTDTAPPTLY-UHFFFAOYSA-N (7-iodo-3,4-dihydro-1h-isoquinolin-2-yl) 2,2,2-trifluoroacetate Chemical compound C1=C(I)C=C2CN(OC(=O)C(F)(F)F)CCC2=C1 OCQJSTDTAPPTLY-UHFFFAOYSA-N 0.000 description 1
- DMOKXRFQTGOLRW-UHFFFAOYSA-N (7-nitro-3,4-dihydro-1h-isoquinolin-2-yl) 2,2,2-trifluoroacetate Chemical compound C1CN(OC(=O)C(F)(F)F)CC2=CC([N+](=O)[O-])=CC=C21 DMOKXRFQTGOLRW-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- APQIUTYORBAGEZ-UHFFFAOYSA-N 1,1-dibromoethane Chemical compound CC(Br)Br APQIUTYORBAGEZ-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VPKAHUMPZYVNIV-UHFFFAOYSA-N 1,4-dihydroisoquinoline Chemical compound C1=CC=C2CC=NCC2=C1 VPKAHUMPZYVNIV-UHFFFAOYSA-N 0.000 description 1
- LXIDSOCBAAMGJX-UHFFFAOYSA-N 1-benzylbenzimidazol-2-amine Chemical compound NC1=NC2=CC=CC=C2N1CC1=CC=CC=C1 LXIDSOCBAAMGJX-UHFFFAOYSA-N 0.000 description 1
- JZHGRUMIRATHIU-UHFFFAOYSA-N 1-ethenyl-3-methylbenzene Chemical compound CC1=CC=CC(C=C)=C1 JZHGRUMIRATHIU-UHFFFAOYSA-N 0.000 description 1
- JZUMPNUYDJBTNO-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 JZUMPNUYDJBTNO-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical class C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- OFGDSGVGRWPQJQ-UHFFFAOYSA-N 1h-imidazol-1-ium;acetate Chemical class CC(O)=O.C1=CNC=N1 OFGDSGVGRWPQJQ-UHFFFAOYSA-N 0.000 description 1
- VWUCIBOKNZGWLX-UHFFFAOYSA-N 1h-imidazol-1-ium;bromide Chemical compound [Br-].C1=C[NH+]=CN1 VWUCIBOKNZGWLX-UHFFFAOYSA-N 0.000 description 1
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1h-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 1
- VVAKEQGKZNKUSU-UHFFFAOYSA-N 2,3-dimethylaniline Chemical compound CC1=CC=CC(N)=C1C VVAKEQGKZNKUSU-UHFFFAOYSA-N 0.000 description 1
- VMHIABFFPVFYNK-UHFFFAOYSA-N 2-(2,3-dimethylphenyl)-3,4-dihydro-1h-isoquinoline Chemical compound CC1=CC=CC(N2CC3=CC=CC=C3CC2)=C1C VMHIABFFPVFYNK-UHFFFAOYSA-N 0.000 description 1
- WJBMRZAHTUFBGE-UHFFFAOYSA-N 2-(3-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC(CCN)=C1 WJBMRZAHTUFBGE-UHFFFAOYSA-N 0.000 description 1
- ZSZCXAOQVBEPME-UHFFFAOYSA-N 2-(4-bromophenyl)ethanamine Chemical compound NCCC1=CC=C(Br)C=C1 ZSZCXAOQVBEPME-UHFFFAOYSA-N 0.000 description 1
- OYBZNZWJLAXIJL-UHFFFAOYSA-N 2-(chloromethyl)-1h-imidazole;hydrochloride Chemical compound Cl.ClCC1=NC=CN1 OYBZNZWJLAXIJL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- PJOKSXRKFYRAEI-AWEZNQCLSA-N 2-o-tert-butyl 3-o-ethyl (3s)-7-(trifluoromethylsulfonyloxy)-3,4-dihydro-1h-isoquinoline-2,3-dicarboxylate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)C=C2CN(C(=O)OC(C)(C)C)[C@H](C(=O)OCC)CC2=C1 PJOKSXRKFYRAEI-AWEZNQCLSA-N 0.000 description 1
- BIBBEZSQLIJAGX-AWEZNQCLSA-N 2-o-tert-butyl 3-o-ethyl (3s)-7-hydroxy-3,4-dihydro-1h-isoquinoline-2,3-dicarboxylate Chemical compound C1=C(O)C=C2CN(C(=O)OC(C)(C)C)[C@H](C(=O)OCC)CC2=C1 BIBBEZSQLIJAGX-AWEZNQCLSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- NKSZCPBUWGZONP-UHFFFAOYSA-N 3,4-dihydroisoquinoline Chemical compound C1=CC=C2C=NCCC2=C1 NKSZCPBUWGZONP-UHFFFAOYSA-N 0.000 description 1
- VXUMRYMTYKDWMO-UHFFFAOYSA-N 3-bromo-4-methylbenzonitrile Chemical compound CC1=CC=C(C#N)C=C1Br VXUMRYMTYKDWMO-UHFFFAOYSA-N 0.000 description 1
- SUISZCALMBHJQX-UHFFFAOYSA-N 3-bromobenzaldehyde Chemical compound BrC1=CC=CC(C=O)=C1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 1
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 1
- MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical compound ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 1
- ILZWWSQOYWMXBQ-UHFFFAOYSA-N 4-(1,2,3,4-tetrahydroisoquinolin-5-ylmethyl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1CC1=CC=CC2=C1CCNC2 ILZWWSQOYWMXBQ-UHFFFAOYSA-N 0.000 description 1
- VGBIUJZPMSGTGK-UHFFFAOYSA-N 4-(3-bromophenyl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylic acid Chemical compound OC(=O)N1CCC=2NC=NC=2C1C1=CC=CC(Br)=C1 VGBIUJZPMSGTGK-UHFFFAOYSA-N 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- OGJDAFUTVFCYRA-UHFFFAOYSA-N 4-[[2-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]-3,4-dihydro-1h-isoquinolin-5-yl]methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CC1=CC=CC2=C1CCN(CC=1N(C=NC=1)CC=1C=CC(=CC=1)C#N)C2 OGJDAFUTVFCYRA-UHFFFAOYSA-N 0.000 description 1
- YYSHXPJUDDMESB-UHFFFAOYSA-N 4-[[5-(1,2,3,4-tetrahydroquinolin-2-ylmethyl)imidazol-1-yl]methyl]benzonitrile;hydrochloride Chemical compound Cl.C1=CC(C#N)=CC=C1CN1C(CC2NC3=CC=CC=C3CC2)=CN=C1 YYSHXPJUDDMESB-UHFFFAOYSA-N 0.000 description 1
- SAOZYMDZSCILTC-UHFFFAOYSA-N 4-[[5-(1h-imidazo[4,5-b]pyridin-2-ylmethyl)imidazol-1-yl]methyl]benzonitrile;hydrochloride Chemical compound Cl.C1=CC(C#N)=CC=C1CN1C(CC=2NC3=NC=CC=C3N=2)=CN=C1 SAOZYMDZSCILTC-UHFFFAOYSA-N 0.000 description 1
- WEMHHDUTZJMSED-UHFFFAOYSA-N 4-[[5-(2h-benzotriazol-4-ylmethyl)imidazol-1-yl]methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CN1C(CC=2C3=NNN=C3C=CC=2)=CN=C1 WEMHHDUTZJMSED-UHFFFAOYSA-N 0.000 description 1
- PLKIRHHMGIRORC-UHFFFAOYSA-N 4-[[5-(2h-benzotriazol-4-ylmethyl)imidazol-1-yl]methyl]benzonitrile;hydrochloride Chemical compound Cl.C1=CC(C#N)=CC=C1CN1C(CC=2C3=NNN=C3C=CC=2)=CN=C1 PLKIRHHMGIRORC-UHFFFAOYSA-N 0.000 description 1
- ZGBXLKKXQIDNAO-UHFFFAOYSA-N 4-[[5-(benzotriazol-2-ylmethyl)imidazol-1-yl]methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CN1C(CN2N=C3C=CC=CC3=N2)=CN=C1 ZGBXLKKXQIDNAO-UHFFFAOYSA-N 0.000 description 1
- RQXQVCLGVCEQDW-UHFFFAOYSA-N 4-[[5-(chloromethyl)imidazol-1-yl]methyl]benzonitrile;hydrochloride Chemical compound Cl.ClCC1=CN=CN1CC1=CC=C(C#N)C=C1 RQXQVCLGVCEQDW-UHFFFAOYSA-N 0.000 description 1
- DBDCSICRTGTQLZ-UHFFFAOYSA-N 4-[[5-[(2,3-dioxoindol-1-yl)methyl]imidazol-1-yl]methyl]benzonitrile;4-[[5-(3h-imidazo[4,5-c]pyridin-2-ylmethyl)imidazol-1-yl]methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CN1C(CC=2NC3=CN=CC=C3N=2)=CN=C1.C12=CC=CC=C2C(=O)C(=O)N1CC1=CN=CN1CC1=CC=C(C#N)C=C1 DBDCSICRTGTQLZ-UHFFFAOYSA-N 0.000 description 1
- XUZHAKAWQBPLFB-UHFFFAOYSA-N 4-[[5-[(4-phenylindol-1-yl)methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CN1C(CN2C3=CC=CC(=C3C=C2)C=2C=CC=CC=2)=CN=C1 XUZHAKAWQBPLFB-UHFFFAOYSA-N 0.000 description 1
- OKAAHZMJCKMXSF-UHFFFAOYSA-N 4-[[5-[(6-bromo-1-oxo-3,4-dihydroisoquinolin-2-yl)methyl]imidazol-1-yl]methyl]benzonitrile;hydrochloride Chemical compound Cl.C1CC2=CC(Br)=CC=C2C(=O)N1CC1=CN=CN1CC1=CC=C(C#N)C=C1 OKAAHZMJCKMXSF-UHFFFAOYSA-N 0.000 description 1
- OUXBTPZRIGINDA-UHFFFAOYSA-N 4-[[5-[(6-bromo-3,4-dihydro-1h-isoquinolin-2-yl)methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound C1CC2=CC(Br)=CC=C2CN1CC1=CN=CN1CC1=CC=C(C#N)C=C1 OUXBTPZRIGINDA-UHFFFAOYSA-N 0.000 description 1
- BFKOIKXIALHLNO-UHFFFAOYSA-N 4-[[5-[(7-iodo-3,4-dihydro-1h-isoquinolin-2-yl)methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound C1C2=CC(I)=CC=C2CCN1CC1=CN=CN1CC1=CC=C(C#N)C=C1 BFKOIKXIALHLNO-UHFFFAOYSA-N 0.000 description 1
- RCXXSJHAEUJJBX-UHFFFAOYSA-N 4-[[5-[(7-nitro-3,4-dihydro-1h-isoquinolin-2-yl)methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound C1C2=CC([N+](=O)[O-])=CC=C2CCN1CC1=CN=CN1CC1=CC=C(C#N)C=C1 RCXXSJHAEUJJBX-UHFFFAOYSA-N 0.000 description 1
- ZWOYXXFYNDUNAG-UHFFFAOYSA-N 4-[[5-[2-(7-bromo-3,4-dihydro-1h-isoquinolin-2-yl)-2-oxoethyl]imidazol-1-yl]methyl]benzonitrile;hydrochloride Chemical compound Cl.C1C2=CC(Br)=CC=C2CCN1C(=O)CC1=CN=CN1CC1=CC=C(C#N)C=C1 ZWOYXXFYNDUNAG-UHFFFAOYSA-N 0.000 description 1
- XFPJJWBMTNBICC-UHFFFAOYSA-N 4-[[5-[[4-(2-methylphenyl)indol-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound CC1=CC=CC=C1C1=CC=CC2=C1C=CN2CC1=CN=CN1CC1=CC=C(C#N)C=C1 XFPJJWBMTNBICC-UHFFFAOYSA-N 0.000 description 1
- AWOVNFQRKZKDJM-UHFFFAOYSA-N 4-[[5-[[7-(2-methylphenyl)-3,4-dihydro-1h-isoquinolin-2-yl]methyl]imidazol-1-yl]methyl]benzonitrile Chemical compound CC1=CC=CC=C1C1=CC=C(CCN(CC=2N(C=NC=2)CC=2C=CC(=CC=2)C#N)C2)C2=C1 AWOVNFQRKZKDJM-UHFFFAOYSA-N 0.000 description 1
- VXWVFZFZYXOBTA-UHFFFAOYSA-N 5-bromo-1h-indole Chemical compound BrC1=CC=C2NC=CC2=C1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 1
- KSONICAHAPRCMV-UHFFFAOYSA-N 5-bromo-2,3-dihydroinden-1-one Chemical compound BrC1=CC=C2C(=O)CCC2=C1 KSONICAHAPRCMV-UHFFFAOYSA-N 0.000 description 1
- LMIQERWZRIFWNZ-UHFFFAOYSA-N 5-hydroxyindole Chemical compound OC1=CC=C2NC=CC2=C1 LMIQERWZRIFWNZ-UHFFFAOYSA-N 0.000 description 1
- BHCMXJKPZOPRNN-UHFFFAOYSA-N 5-iodo-1h-imidazole Chemical compound IC1=CN=CN1 BHCMXJKPZOPRNN-UHFFFAOYSA-N 0.000 description 1
- PCRODLZZZPRWHB-UHFFFAOYSA-N 5-phenoxy-1h-imidazole Chemical compound C=1C=CC=CC=1OC1=CNC=N1 PCRODLZZZPRWHB-UHFFFAOYSA-N 0.000 description 1
- URDGCPQHZSDBRG-UHFFFAOYSA-N 6-bromo-1,2,3,4-tetrahydroisoquinoline Chemical compound C1NCCC2=CC(Br)=CC=C21 URDGCPQHZSDBRG-UHFFFAOYSA-N 0.000 description 1
- PJXKCQFWSNNAEY-UHFFFAOYSA-N 7-(2-methylphenyl)-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.CC1=CC=CC=C1C1=CC=C(CCNC2)C2=C1 PJXKCQFWSNNAEY-UHFFFAOYSA-N 0.000 description 1
- OYODEQFZAJVROF-UHFFFAOYSA-N 7-bromo-1,2,3,4-tetrahydroisoquinoline Chemical compound C1CNCC2=CC(Br)=CC=C21 OYODEQFZAJVROF-UHFFFAOYSA-N 0.000 description 1
- FFCFXJXBXUOFIU-UHFFFAOYSA-N 7-iodo-1,2,3,4-tetrahydro-isoquinoline Chemical compound C1CNCC2=CC(I)=CC=C21 FFCFXJXBXUOFIU-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 101100346171 Arabidopsis thaliana MORC3 gene Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 238000006407 Bischler-Napieralski reaction Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101100168604 Candida albicans (strain SC5314 / ATCC MYA-2876) CRH12 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000579895 Chlorostilbon Species 0.000 description 1
- HOSKTMXYPLFURR-MQWQBNKOSA-N Cl.Cl.C(=O)(OCC)[C@@H]1N(CCC2=CC=CC=C12)CC1=CN=CN1CC1=CC=C(C=C1)C#N Chemical compound Cl.Cl.C(=O)(OCC)[C@@H]1N(CCC2=CC=CC=C12)CC1=CN=CN1CC1=CC=C(C=C1)C#N HOSKTMXYPLFURR-MQWQBNKOSA-N 0.000 description 1
- MEVHCYINSDANGP-UHFFFAOYSA-N Cl.Cl.C(C)(=O)NC1=CC=C2CCN(CC2=C1)CC1=CN=CN1CC1=CC=C(C=C1)C#N Chemical compound Cl.Cl.C(C)(=O)NC1=CC=C2CCN(CC2=C1)CC1=CN=CN1CC1=CC=C(C=C1)C#N MEVHCYINSDANGP-UHFFFAOYSA-N 0.000 description 1
- NIKUPINXBFIFIE-SYXKTQFYSA-N Cl.Cl.CC1=C(C=CC=C1C)NC(=O)[C@@H]1N(CC2=CC=CC=C2C1)CC1=CN=CN1CC1=CC=C(C=C1)C#N Chemical compound Cl.Cl.CC1=C(C=CC=C1C)NC(=O)[C@@H]1N(CC2=CC=CC=C2C1)CC1=CN=CN1CC1=CC=C(C=C1)C#N NIKUPINXBFIFIE-SYXKTQFYSA-N 0.000 description 1
- NKLHRBXOQHADQA-UHFFFAOYSA-N Cl.Cl.IC1=CC=C2CCN(CC2=C1)CC1=CN=CN1CC1=CC=C(C=C1)C#N Chemical compound Cl.Cl.IC1=CC=C2CCN(CC2=C1)CC1=CN=CN1CC1=CC=C(C=C1)C#N NKLHRBXOQHADQA-UHFFFAOYSA-N 0.000 description 1
- CONLSRGFUXDWOV-QDSLRZTOSA-N Cl.Cl.OC[C@H]1N(CCC2=CC=C(C=C12)C1=CC=CC=C1)CC1=CN=CN1CC1=CC=C(C=C1)C#N Chemical compound Cl.Cl.OC[C@H]1N(CCC2=CC=C(C=C12)C1=CC=CC=C1)CC1=CN=CN1CC1=CC=C(C=C1)C#N CONLSRGFUXDWOV-QDSLRZTOSA-N 0.000 description 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 101100168607 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UTR2 gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000006612 Transducin Human genes 0.000 description 1
- 108010087042 Transducin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- OGZRCNMBCSQOAM-UHFFFAOYSA-N [5-[(4-cyanophenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-yl] 2,2,2-trifluoroacetate Chemical compound C1=CC=C2CN(OC(=O)C(F)(F)F)CCC2=C1CC1=CC=C(C#N)C=C1 OGZRCNMBCSQOAM-UHFFFAOYSA-N 0.000 description 1
- QJDRJYYYSHHGJV-UHFFFAOYSA-N [5-[2-(3-methylphenyl)ethenyl]-3,4-dihydro-1h-isoquinolin-2-yl] 2,2,2-trifluoroacetate Chemical compound CC1=CC=CC(C=CC=2C=3CCN(CC=3C=CC=2)OC(=O)C(F)(F)F)=C1 QJDRJYYYSHHGJV-UHFFFAOYSA-N 0.000 description 1
- KIPWHSSTNMNUDS-UHFFFAOYSA-N [N].C1NCCC2=CC=CC=C12 Chemical compound [N].C1NCCC2=CC=CC=C12 KIPWHSSTNMNUDS-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- NZHXEWZGTQSYJM-UHFFFAOYSA-N [bromo(diphenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Br)C1=CC=CC=C1 NZHXEWZGTQSYJM-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229940060587 alpha e Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- NLHWCTNYFFIPJT-UHFFFAOYSA-N disodium bis(trimethylsilyl)azanide Chemical compound [Na+].[Na+].C[Si](C)(C)[N-][Si](C)(C)C.C[Si](C)(C)[N-][Si](C)(C)C NLHWCTNYFFIPJT-UHFFFAOYSA-N 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229910052876 emerald Inorganic materials 0.000 description 1
- 239000010976 emerald Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- FFSCDOTYKKNTCB-UHFFFAOYSA-N ethyl 5-chloro-1-[[3-[(4-cyanophenyl)methyl]imidazol-4-yl]methyl]indole-2-carboxylate Chemical compound CCOC(=O)C1=CC2=CC(Cl)=CC=C2N1CC1=CN=CN1CC1=CC=C(C#N)C=C1 FFSCDOTYKKNTCB-UHFFFAOYSA-N 0.000 description 1
- LWKIFKYHCJAIAB-UHFFFAOYSA-N ethyl 5-chloro-1h-indole-2-carboxylate Chemical compound ClC1=CC=C2NC(C(=O)OCC)=CC2=C1 LWKIFKYHCJAIAB-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000006130 geranylgeranylation Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- WFNASTYGEKUMIY-UHFFFAOYSA-N hydron;1h-imidazol-5-ylmethanol;chloride Chemical compound Cl.OCC1=CN=CN1 WFNASTYGEKUMIY-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- PRJKNHOMHKJCEJ-UHFFFAOYSA-N imidazol-4-ylacetic acid Chemical compound OC(=O)CC1=CN=CN1 PRJKNHOMHKJCEJ-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- ODSJRSDWANAFRF-UHFFFAOYSA-N methyl n-cyanomethanimidate Chemical compound COC=NC#N ODSJRSDWANAFRF-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000008692 neointimal formation Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- ZBRJXVVKPBZPAN-UHFFFAOYSA-L nickel(2+);triphenylphosphane;dichloride Chemical compound [Cl-].[Cl-].[Ni+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 ZBRJXVVKPBZPAN-UHFFFAOYSA-L 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 150000004962 phenylmethylimidazoles Chemical class 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108700026239 src Genes Proteins 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- SQQZLHPNVULMNZ-IBGZPJMESA-N tert-butyl (3s)-3-[(3-chlorophenyl)methylcarbamoyl]-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound O=C([C@@H]1CC2=CC=CC=C2CN1C(=O)OC(C)(C)C)NCC1=CC=CC(Cl)=C1 SQQZLHPNVULMNZ-IBGZPJMESA-N 0.000 description 1
- CLJKMPQUJJDTEO-UHFFFAOYSA-N tert-butyl 7-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1=C2CN(C(=O)OC(C)(C)C)CCC2=CC=C1C1=CC=CC=C1 CLJKMPQUJJDTEO-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Definitions
- Ras protein is part of a signalling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation.
- Biological and biochemical studies of Ras action indicate that Ras functions like a G-regulatory protein.
- Ras In the inactive state, Ras is bound to GDP.
- Ras Upon growth factor receptor activation Ras is induced to exchange GDP for GTP and undergoes a conformational change.
- the GTP-bound form of Ras propagates the growth stimulatory signal until the signal is terminated by the intrinsic GTPase activity of Ras, which returns the protein to its inactive GDP bound form (D.R. Lowy and D.M. Willumsen, Ann. Rev. Biochem. 62:851- 891 (1993)).
- Ras must be localized to the plasma membrane for both normal and oncogenic functions. At least 3 post-translational modifications are involved with Ras membrane localization, and all 3 modifications occur at the C-terminus of Ras.
- the Ras C-terminus contains a sequence motif termed a "CAAX" or box (Cys is cysteine, Aaa is an aliphatic amino acid, the Xaa is any amino acid) (Willumsen et al, Nature 370:583-586 (1984)).
- this motif serves as a signal sequence for the enzymes farnesyl-protein transferase or geranylgeranyl-protein transferase, which catalyze the alkylation of the cysteine residue of the CAAX motif with a C 15 or C20 isoprenoid, respectively.
- farnesyl-protein transferase or geranylgeranyl-protein transferase which catalyze the alkylation of the cysteine residue of the CAAX motif with a C 15 or C20 isoprenoid, respectively.
- farnesylated proteins include the Ras-related GTP-binding proteins such as Rho, fungal mating factors, the nuclear lamins, and the gamma subunit of transducin. James, et al., J. Biol. Chem. 269, 14182 (1994) have identified a peroxisome associated protein Pxf which is also farnesylated. James, et al., have also suggested that there are farnesylated proteins of unknown structure and function in addition to those listed above.
- Farnesyl-protein transferase utilizes farnesyl pyrophosphate to covalently modify the Cys thiol group of the Ras CAAX box with a farnesyl group (Reiss et al, Cell, 62:81-88 (1990); Schaber et al, J. Biol Chem., 265:14701-14704 (1990); Schafer et al, Science, 249:1133-1139 (1990); Manne et al, Proc. Natl Acad. Sci USA, ⁇ 7:7541-7545 (1990)).
- Inhibition of farnesyl pyrophosphate biosynthesis by inhibiting HMG-CoA reductase blocks Ras membrane localization in cultured cells.
- direct inhibition of farnesyl- protein transferase would be more specific and attended by fewer side effects than would occur with the required dose of a general inhibitor of isoprene biosynthesis.
- FPTase farnesyl-protein transferase
- FPP farnesyl diphosphate
- Ras protein substrates
- the peptide derived inhibitors that have been described are generally cysteine containing molecules that are related to the CAAX motif that is the signal for protein prenylation.
- Such inhibitors may inhibit protein prenylation while serving as alternate substrates for the farnesyl-protein transferase enzyme, or may be purely competitive inhibitors (U.S. Patent 5,141,851, University of Texas; N.E. Kohl et al, Science, 260: 1934-1937 (1993); Graham, et al., J. Med. Chem., 37, 725 (1994)).
- deletion of the thiol from a CAAX derivative has been shown to dramatically reduce the inhibitory potency of the compound.
- the thiol group potentially places limitations on the therapeutic application of FPTase inhibitors with respect to pharmacokinetics, pharmacodynamics and toxicity. Therefore, a functional replacement for the thiol is desirable.
- farnesyl-protein transferase inhibitors are inhibitors of proliferation of vascular smooth muscle cells and are therefore useful in the prevention and therapy of arteriosclerosis and diabetic disturbance of blood vessels (JP H7- 112930). It has also recently been disclosed that certain 1,2,3,4- tetrahydroisoquinoline peptidomimetic compounds, some of which incorporate an imidazole moiety, are inhibitors of FPTase (U.S. Pat. No. 5,439,918, EP 0 618 221 A2 and EP 0 675 112 Al ).
- the present invention comprises peptidomimetic 1,2,3,4- tetrahydroisoquinolines and homologous compounds which inhibit farnesyl-protein transferase. Furthermore, these compounds differ from such heterocyclic compounds previously described as inhibitors of farnesyl-protein transferase with respect to the alkyl or heteroatom containing linker between the tetrahydroisoquinoline nitrogen and the imidazolyl moiety, and with respect to the lack of a thiol moiety in the instant compounds. Further contained in this invention are chemotherapeutic compositions containing these famesyl transferase inhibitors and methods for their production.
- the compounds of this invention are useful in the inhibition of farnesyl-protein transferase and the famesylation of the oncogene protein Ras.
- the inhibitors of farnesyl-protein transferase are illustrated by the formula I:
- Rla, Rib nd lc are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl,
- R2a ? R2b' a n R ⁇ b" are independently hydrogen, NH2 or -(CR112) V A3(CR12 2 ) W R13; or R2b' and R ⁇ b" are combined as O;
- R3a and R ⁇ b are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or substituted C3- ClO cycloalkyl, unsubstituted or substituted C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 perfluoroalkyl,
- R4 is independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl,
- R5 is independently selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, perfluoroalkyl, F, Cl, Br, R80-, R9s(0) m -, R S C(0)NR8-, CN, N02, (R8)2N-C-(NR8)-, R8C(0)-, R8 ⁇ C(0)-, N3, -N(R8)2, or R9 ⁇ C(0)NR8-, and c) C1-C6 alkyl, unsubstituted or substituted by perfluoroalkyl,
- R is independently selected from hydrogen, C1-C6 alkyl, benzyl, 2,2,2- trifluoroethyl and aryl;
- R9 is independently selected from C1-C6 alkyl and aryl
- R 10 is selected from: H; R 8 C(0)-; R9S(0) m -; unsubstituted or substituted Cl-4 alkyl, unsubstituted or substituted C3-6 cycloalkyl, unsubstituted or substituted heterocycle, unsubstituted or substituted aryl, substituted aroyl, unsubstituted or substituted heteroaroyl, substituted arylsulfonyl, unsubstituted or substituted heteroarylsulfonyl, wherein the substituted group is substituted with one or two substituents selected from: a) Cl-4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO,
- Rl 1 and Rl2 are independently selected from: a) hydrogen, b) C1-C6 alkyl unsubstituted or substituted by C2-C20 alkenyl,
- Rl is selected from: a) hydrogen, b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C3-C10 cycloalkyl, C2-C2O alkenyl, C2-C2O alkynyl, C1-C2O perfluoroalkyl, allyloxy, F, Cl, Br, R80-, R9S(0) m -, R 8 C(0)NR8-, CN, N02, R82N-C(NR8)-, R8C(0)-, N3, -N(R 8 )2, (R9)2NC(0)- or
- R9 ⁇ C(0)NR8- and c) C1-C alkyl unsubstituted or substituted by substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C3-C10 cycloalkyl, C2-C20 alkenyl, C2-C2O alkynyl, C2- C20 perfluoroalkyl, F, Cl, Br, R8O-, R9S(0) m -,
- G, J, L and M are independently selected from: CHy or N;
- T is selected from: N, CR 2 ' 0 r CR2b'R2b" ;
- V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, provided that V is not hydrogen if Al is S(0)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(0)m; and provided that V is not imidazolyl;
- W is a heterocycle
- inhibitors of farnesyl-protein transferase are illustrated by the formula A:
- Rla, Rib and Rl° are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl,
- R9OC(0)NR8- c) C1-C alkyl unsubstituted or substituted by unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R8O-, R9S(0) m - .
- R S C(0)NR8-,
- R 2a , R 2 ' and R 2 b" are independently hydrogen or -(CRH2)VA3(CR1 2 2)WR 13 ; or R 2 ' and R 2 " are combined as O;
- R3 and R3b are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or substituted C3- ClO cycloalkyl, unsubstituted or substituted C2-C6 alkenyl, C2-C6 alkynyl, halogen, C1-C6 perfluoroalkyl, R 9 0-, R9s(0)m-, R S C(0)NR8-, (R8)2NC(0)-,
- R4 is independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl,
- R 9 S(0)m-, R8C(0)NR8-, CN, NO2, R S 2N-C(NR8)-, R8C(0)-, R8 ⁇ C(0)-, N3, -N(R8)2, or R9 ⁇ C(0)NR8-, and c) C1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, perfluoroalkyl, F, Cl, Br, R80-, R9s(0) m -, R8C(0)NH-, CN, H2N-C(NH)-, R8C(0)-, R8 ⁇ C(0)-, N3, -N(R8)2, or R8 ⁇ C(0)NH-, provided that R4 is not unsubstituted or substituted imidazolyl;
- R5 is independently selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, perfluoroalkyl, F, Cl, Br, R80-, R9S(0) m -, R S C(0)NR8-, CN, N ⁇ 2, (R8)2N-C-(NR8)-, R8C(0)-, R8 ⁇ C(0)-, N3, -N(R8)2, or R9 ⁇ C(0)NR8-, and c) C1-C6 alkyl, unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R80-, R9s(0) m -, R S C(0)NR8-, CN, (R8) 2 N-
- R is independently selected from hydrogen, C1-C alkyl, benzyl, 2,2,2- trifluoroethyl and aryl;
- R9 is independently selected from C1-C6 alkyl and aryl
- RlO is selected from: H; R8C(0)-; R9s(0) m -. unsubstituted or substituted Cl-4 alkyl, unsubstituted or substituted C3-6 cycloalkyl, unsubstituted or substituted heterocycle, unsubstituted or substituted aryl, substituted aroyl, unsubstituted or substituted heteroaroyl, substituted arylsulfonyl, unsubstituted or substituted heteroarylsulfonyl, wherein the substituted group is substituted with one or two substituents selected from: a) Cl-4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO,
- Rl l and Rl2 are independently selected from: a) hydrogen, b) Cl-C6 alkyl unsubstituted or substituted by C2-C20 alkenyl, R 8 0-, R9s(0) m -, R8C(0)NR8-, CN, N3,
- Rl3 is selected from: a) hydrogen, b) substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, C3-C10 cycloalkyl, C2-C2O alkenyl, C2-C2O alkynyl, C1-C2O perfluoroalkyl, allyloxy, F, Cl, Br, R80-, R9S(0) m -, R8C(0)NR8-, CN, NO2,
- V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, provided that V is not hydrogen if Al is S(0)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(0)m; and provided that V is not imidazolyl; W is a heterocycle;
- Rla and Rlc are independently selected from: hydrogen, C3-C10 cycloalkyl, R8O-, -N(R8) 2 , F or C1-C6 alkyl;
- Ri is independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C3-C6 cycloalkyl, R 0-, -N(R8) 2 or C2-C6 alkenyl, c) C1-C6 alkyl unsubstituted or substituted by unsubstituted or substituted aryl, heterocycle, C3-C6 cycloalkyl, C2-C6 alkenyl, R80-, or -N(R8) 2 ;
- R 2a and R 2 b' are independently selected from: H; C1-C6 alkyl,
- R3a and R3b are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted C2-C alkenyl, C 2 -
- R4 is independently selected from: a) hydrogen, b) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 0-, R8C(0)NR8-, CN, N02, (R8)2N-C(NR8)-, R8C(0)-, R8 ⁇ C(0)-, -N(R8)2, or R9 ⁇ C(0)NR8-, and c) C l -C6 alkyl substituted by C l -C6 perfluoroalkyl, R80- , R8C(0)NR8-, (R8) 2 N-C(NR8)-, R8C(0)-, R8 ⁇ C(0)-, -N(R8)2, or R9 ⁇ C(0)NR8-;
- R5 is selected from: a) hydrogen, b) C2-C6 aikenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C1-C6 perfluoroalkyl, F, Cl, R80-, R9s(0) m -, R S C(0)NR8-, CN, N02, (R8)2N-C(NR8)-, R8C(0)-, R8 ⁇ C(0)-, -N(R8) 2J or
- R9 ⁇ C(0)NR8- and c) C1-C alkyl unsubstituted or substituted by C1-C6 perfluoroalkyl, F, Cl, R80-, R9S(0) m -, R S C(0)NR8-, CN, (R8)2N-C(NR8)-, R8C(0)-, R8 ⁇ C(0)-, -N(R8) 2 , or R90C(0)NR8- ;
- R6 and R ⁇ are independently selected from:
- R8 is independently selected from hydrogen, C1-C6 alkyl, benzyl, 2,2,2- trifluoroethyl and aryl;
- R9 is independently selected from C1-C6 alkyl and aryl;
- V is selected from: a) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, and b) aryl;
- W is a heterocycle selected from pyrrolidinyl, triazolyl, imidazolyl, pyridinyl, thiazolyl, indolyl, quinolinyl, or isoquinolinyl;
- the inhibitors of farnesyl-protein transferase are illustrated by the formula Al:
- Rla and Rlc are independently selected from: hydrogen, C3-C10 cycloalkyl, R8O-, -N(R8) 2 , F or C1-C6 alkyl;
- Rib is independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, C3-C6 cycloalkyl, R 8 0-, -N(R8) 2 or C2-C6 alkenyl, c) C1-C6 alkyl unsubstituted or substituted by unsubstituted or substituted aryl, heterocycle, C3-C6 cycloalkyl, C2-C6 alkenyl, R8O-, or -N(R8) 2 ;
- R 2 a is selected from: H; C1-C6 alkyl, NH2
- R3 and R3b are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted C2-C6 alkenyl, C 2 - C6 alkynyl, halogen, C1-C6 perfluoroalkyl, R9 ⁇ -, R 9 S(0) m -, R8C(0)NR8-, (R8)2NC(0)-, R9C(0)0-, R82N- C(NR8)-, CN, N ⁇ 2, R 8 C(0)-, N3, -N(R8) 2 ⁇ or
- R9 ⁇ C(0)NR8- c) unsubstituted Cl-C alkyl, d) substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R 9 0-,
- R 9 S(0) m -, R8C(0)NR8-, (R8)2NC(0)-, R8 2 N-C(NR8)-, CN, R8C(0)-, N3, -N(R8)2, and R9 ⁇ C(0)-NR8-;
- R4 is independently selected from: a) hydrogen, b) C 1 -C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C 1 -C6 perfluoroalkyl, F, Cl, R8O-, R C(0)NR8-, CN, N02, (R8)2N-C(NR8)-, R8C(0)-, R8 ⁇ C(0)-, -N(R8)2, or R9 ⁇ C(0)NR8-, and c) C1-C6 alkyl substituted by -C6 perfluoroalkyl, R 8 0-,
- R5 is selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C1-C6 perfluoroalkyl, F, Cl, R8O-, R9s(0) m -, R S C(0)NR8-, CN, N02, (R8)2N-C(NR8)-, R8C(0)-, R8 ⁇ C(0)-, -N(R8) 2 , or R9 ⁇ C(0)NR8-, and c) C1-C6 alkyl unsubstituted or substituted by C1-C6 perfluoroalkyl, F, Cl, R8O-, R9S(0) m -, R S C(0)NR8-, CN, (R8)2N-C(NR8)-, R8C(0)-, R8 ⁇ C(0)-, -N(R8)2, or R90C(0)NR8- ;
- R6 and R ⁇ are independently selected from:
- R8 is independently selected from hydrogen, C1-C6 alkyl, benzyl, 2,2,2- trifluoroethyl and aryl;
- R9 is independently selected from C1-C6 alkyl and aryl
- G and M are independently selected from: CHy or N;
- V is selected from: a) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, and b) aryl;
- W is a heterocycle selected from pyrrolidinyl, triazolyl, imidazolyl, pyridinyl, thiazolyl, indolyl, quinolinyl, or isoquinolinyl;
- n 0, 1 or 2
- n 0, 1, 2, 3 or 4
- p is 1, 2 or 3
- q is 0, 1 or 2, provided that q is not 0 or 1 if X is O
- r is 0 to 5, provided that r is 0 when V is hydrogen
- s is 1 or 2
- t is 1
- y is 1 or 2;
- Rla and Rlc are independently selected from: hydrogen, C3-C10 cycloalkyl, R80-, -N(R8) 2 , F or C1-C6 alkyl;
- R is independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C10 cycloalkyl, R 8 0-, -N(R8) 2 , F or C2-C6 alkenyl, c) unsubstituted or substituted C1-C alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, R8Q ⁇ and -N(R8) 2 ; R 2a and R 2 b' are independently selected from selected from: H; Cl-
- R3a and R3b are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted C2-C6 alkenyl, C 2 - C6 alkynyl, halogen, C1-C6 perfluoroalkyl, R9 ⁇ -, R9s(0)m- .
- R4 is independently selected from: a) hydrogen, b) aryl, substituted aryl, heterocycle, substituted heterocycle, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R8O-, R8C(0)NR8-, CN, N02,
- R*5a and R ⁇ b are independently hydrogen, Cl-C6 alkyl, cyclopropyl, trifluoromethyl and halogen;
- R6 and R ⁇ are independently selected from: H; Cl-4 alkyl, C3-6 cycloalkyl, aryl, heterocycle, unsubstituted or substituted with one or two: a) Cl-4 alkoxy, b) halogen, or c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;
- R8 is independently selected from hydrogen, C1-C6 alkyl, 2,2,2- trifluoroethyl, benzyl and aryl;
- R9 is independently selected from C1-C6 alkyl and aryl
- V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolinyl, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl, c) aryl, d) C1-C2O alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and e) C2-C2O alkenyl, and provided that V is not hydrogen if A is S(0)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(0)m;
- the inhibitors of famesyl-protein transferase are illustrated by the formula B 1 :
- Rla and Rlc are independently selected from: hydrogen, C3-C10 cycloalkyl, R 0-, -N(R8) 2 , F or C1-C6 alkyl;
- Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C10 cycloalkyl, R 8 0-, -N(R 8 )2, F or C2-C6 alkenyl, c) unsubstituted or substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, R8O- and -N(R8) 2 ;
- R 2a is selected from selected from: H; C1-C6 alkyl,
- R3a and R3b are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted C2-C alkenyl, C2- C6 alkynyl, halogen, C1-C6 perfluoroalkyl, R 9 0-, R 9 S(0)m-, R8C(0)NR8-, (R8)2NC(0)-, R9C(0)0-, R8 2 N- C(NR8)-, CN, N02, R 8 C(0)-, N3, -N(R8)2, or R9 ⁇ C(0)NR8-, c) unsubstituted C1-C6 alkyl, d) substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, unsubstit
- R 9 S(0)m-, R8C(0)NR8-, (R8) 2 NC(0)-, R82N-C(NR8)-, CN, R8C(0)-, N3, -N(R8)2, and R9OC(0)-NR8-;
- R4 is independently selected from: a) hydrogen, b) aryl, substituted aryl, heterocycle, substituted heterocycle, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R80-, R8C(0)NR8-, CN, N02, (R8)2N-C(NR8)-, R8C(0)-, -N(R8) 2 , or R9 ⁇ C(0)NR8-, and c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R80-, R8C(0)NR8-, (R8) 2 N-C(NR8)-, R8C(0)-, -N(R8)2, or R9 ⁇ C(0)NR8-;
- R ⁇ a and R ⁇ b are independently hydrogen, C1-C6 alkyl, cyclopropyl, trifluoromethyl and halogen;
- R6 and R7 are independently selected from:
- R is independently selected from hydrogen, C1-C6 alkyl, 2,2,2- trifluoroethyl, benzyl and aryl;
- R9 is independently selected from C1-C alkyl and aryl
- V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolinyl, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl, c) aryl, d) C1-C2O alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and e) C2-C2O alkenyl, and provided that V is not hydrogen if A is S(0)m and V is not hydrogen
- n 0, 1 or 2
- n 0, 1, 2, 3 or 4
- p is 1, 2 or 3
- q is 0, 1 or 2, provided that q is not 0 or 1 if X is 0
- r is 0 to 5, provided that r is 0 when V is hydrogen
- y is 1 or 2;
- Rla and Rlc are independently selected from: hydrogen, C3-C10 cycloalkyl, R8O-, -N(R8)2, F or C1-C6 alkyl;
- Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C10 cycloalkyl, R 8 0-, -N(R 8 )2, F or C2-C6 alkenyl, c) unsubstituted or substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, R8Q- and -N(R8) 2 ;
- R 2a and R 2 b' are independently selected from selected from: H; Ci-
- R3a and R3b are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted C2-C6 alkenyl, C2- C6 alkynyl, halogen, C1-C6 perfluoroalkyl, R 9 0-, R 9 S(0)m-, R8C(0)NR8-, (R8)2NC(0)-, R 9 C(0)0-, R82N- C(NR8)-, CN, N02, R 8 C(0)-, N3, -N(R8)2, or
- R 9 OC(0)NR8-, c) unsubstituted C1-C6 alkyl, d) substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic,
- R is independently selected from: a) hydrogen, b) aryl, substituted aryl, heterocycle, substituted heterocycle, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 8 0-, R8C(0)NR8-, CN, NO2, (R8)2N-C(NR8)-, R8C(0)-, -N(R8) 2 , or R 9 OC(0)NR8-, and c) C1-C6 alkyl substituted by -C6 perfluoroalkyl, R 8 0-, R8C(0)NR8-, (R8) 2 N-C(NR8)-, R8C(0)-, -N(R8) 2J or R 9 OC(0)NR8-;
- R ⁇ and R ⁇ b are independently hydrogen, C1-C6 alkyl, cyclopropyl, trifluoromethyl and halogen;
- R6 and R ⁇ are independently selected from:
- R8 is independently selected from hydrogen, C1-C6 alkyl, 2,2,2- trifluoroethyl, benzyl and aryl;
- R 9 is independently selected from C1-C6 alkyl and aryl
- V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolinyl, pyridinyl, thiazolyl, oxazolyl, indolyl, quinolinyl, isoquinolinyl, triazolyl and thienyl, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and e) C2-C2O alkenyl, and provided that V is not hydrogen if Al is S(0)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(0)m.
- R a and Rlc are independently selected from: hydrogen, C3-C10 cycloalkyl or C1-C6 alkyl; Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C10 cycloalkyl, R80-, -N(R 8 )2, F or C2-C6 alkenyl, c) Cl-C ⁇ alkyl unsubstituted or substituted by aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, R 8 0-, or
- R 2a and R 2 b' are independently selected from selected from: H; Cl-
- R3a and R3b are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted C2-C6 alkenyl, C 2 - C6 alkynyl, halogen, C1-C6 perfluoroalkyl, R 9 0-, R 9 S(0)m-, R8C(0)NR8-, (R8) 2 NC(0)-, R 9 C(0)0-, R8 2 N- C(NR8)-, CN, N02, R 8 C(0)-, N3, -N(R8) 2 , or
- R90C(0)NR8- c) unsubstituted C1-C6 alkyl, d) substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic,
- R4 is independently selected from: a) hydrogen,
- SUBST1TUTE SHEET (RULE 26) b) aryl, substituted aryl, heterocycle, substituted heterocycle, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 8 0-, R8C(0)NR8-, CN, N02, (R8)2N-C(NR8)-, R8C(0)-, -N(R8)2, or R9 ⁇ C(0)NR8-, and c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R 0-, R8C(0)NR8-, (R8) 2 N-C(NR8)-, R8C(0)-, -N(R8) 2 , or R90C(0)NR8- ;
- R ⁇ a and R ⁇ b are independently hydrogen, ethyl, cyclopropyl or methyl
- R6 and R ⁇ are independently selected from:
- R is independently selected from hydrogen, C1-C6 alkyl, 2,2,2- trifluoroethyl, benzyl and aryl;
- R9 is independently selected from Cl-C ⁇ alkyl and aryl
- Al is selected from: a bond, -C(O)-, O, -N(R8)-, or -S(0) m ;
- n 0, 1 or 2; provided that n is not 0 or 1 if A is a bond, O, -N(R8)-, or S(0)m; m is 0, 1 or 2; p is 0, 1, 2, 3 or 4; q is 0, 1 or 2, provided that q is not 0 or 1 if X is O; r is 1 or 2; and u is independently 0 or 1 ;
- the inhibitors of farnesyl-protein transferase are illustrated by the formula Dl:
- Rla and Rlc are independently selected from: hydrogen, C3-C10 cycloalkyl or C1-C6 alkyl;
- Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C10 cycloalkyl, R 8 0-, -N(R 8 )2, F or C2-C6 alkenyl, c) C1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, R 8 0-, or
- R 2a is selected from selected from: H; C1-C6 alkyl, NH 2 ,
- R3a and R3b are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted C2-C6 alkenyl, C2- C6 alkynyl, halogen, C1-C6 perfluoroalkyl, R9 ⁇ -, R 9 S(0)m-, R8C(0)NR8-, (R8) 2 NC(0)-, R 9 C(0)0-, R 2 N- C(NR8)-, CN, NO2, R 8 C(0)-, N3, -N(R8) 2 , or R 9 OC(0)NR8-, c) unsubstituted C1-C6 alkyl, d) substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, unsubsti
- R 9 S(0)m-, R8C(0)NR8-, (R8)2NC(0)-, R8 2 N-C(NR8)-, CN, R8C(0)-, N3, -N(R8)2, and R 9 OC(0)-NR8-;
- R4 is independently selected from: a) hydrogen, b) aryl, substituted aryl, heterocycle, substituted heterocycle, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R8O-, R8C(0)NR8-, CN, N02, (R8) 2 N-C(NR8)-, R ⁇ C(O)-, -N(R8) 2 , or R OC(0)NR8-, and c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R s O-, R8C(0)NR8-, (R8) 2 N-C(NR8)-, R8C(0)-, -N(R8) 2 , or R90C(0)NR8-;
- R ⁇ and R ⁇ b are independently hydrogen, ethyl, cyclopropyl or methyl
- R6 and R ⁇ are independently selected from:
- SUBS UTE SHEET (RULE 26) unsubstituted or substituted with one or two: a) Cl-4 alkoxy, b) halogen, or c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;
- R is independently selected from hydrogen, C1-C6 alkyl, 2,2,2- trifluoroethyl, benzyl and aryl;
- R9 is independently selected from C1-C6 alkyl and aryl
- Al is selected from: a bond, -C(O)-, O, -N(R8)-, or -S(0) m ;
- Z is selected from: CR 2a , or N; provided that at least Y or Z is N;
- n 0, 1 or 2; provided that n is not 0 or 1 if A is a bond, 0, -N(R8)-, or S(0)m; m is 0, 1 or 2; p is 0, 1, 2, 3 or 4; q is 0, 1 or 2, provided that q is not 0 or 1 if X is O; r is 1 or 2; and y is 1 or 2;
- the inhibitors of farnesyl-protein transferase are illustrated by the formula E:
- Rla and Rlc are independently selected from: hydrogen, R O ⁇ , -N(R8)2, F, C3-C10 cycloalkyl or C1-C6 alkyl;
- Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C10 cycloalkyl, R 8 0-, -N(R 8 )2, F or C2-C6 alkenyl, c) C1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, R80-, or
- R 2a and R 2 b' are independently selected from selected from: H; Cl-
- R3a a nd R3b are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted C2-C6 alkenyl, C2- C6 alkynyl, halogen, C1-C6 perfluoroalkyl, R9 ⁇ -, R 9 S(0)m-, R8C(0)NR8-, (R8) 2 NC(0)-, R 9 C(0)0-, R8 2 N- C(NR8)-, CN, N02, R 8 C(0)-, N3, -N(R8) 2 , or R9 ⁇ C(0)NR8-, c) unsubstituted C1-C6 alkyl, d) substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted ary
- R4 is independently selected from: a) hydrogen, b) aryl, substituted aryl, heterocycle, substituted heterocycle, C1-C6 alkyl, C 2 -C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R80-, R8C(0)NR8-, CN, N ⁇ 2,
- R*5a and R ⁇ b are independently hydrogen, ethyl, cyclopropyl or methyl
- R6 and R ⁇ are independently selected from: H; Cl-4 alkyl, C3-6 cycloalkyl, aryl, heterocycle, unsubstituted or substituted with one or two: a) Cl-4 alkoxy, b) halogen, or c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;
- R8 is independently selected from hydrogen, C1-C6 alkyl, 2,2,2- trifluoroethyl, benzyl and aryl;
- R9 is independently selected from -C6 alkyl and aryl;
- n 0 or 1 ;
- m is 0, 1 or 2;
- p is 0, 1, 2, 3 or 4, provided that p is not 0 if X is a bond or O;
- q is 0, 1 or 2, provided that q is not 0 or 1 if X is O;
- r is 1 or 2; and
- u is independently 0 or 1 ;
- Rla and Rlc are independently selected from: hydrogen, C3-C10 cycloalkyl or C1-C6 alkyl;
- Rib is independently selected from: a) hydrogen,
- R 2a and R 2 b' are independently selected from selected from: H; Cl-
- R a and R3b are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted C2-C6 alkenyl, C2- C alkynyl, halogen, C1-C6 perfluoroalkyl, R 9 0-, R 9 S(0)m-, R8C(0)NR8-, (R8) 2 NC(0)-, R 9 C(0)0-, R8 2 N- C(NR8)-, CN, N02, R 8 C(0)-, N3, -N(R8) 2 , or
- R 9 OC(0)NR8-, c) unsubstituted C1-C6 alkyl, d) substituted C1-C6 alkyl wherein the substituent on the substituted C1-C alkyl is selected from unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic,
- R ⁇ a and R ⁇ b are independently hydrogen, ethyl, cyclopropyl or methyl
- R6 and R ⁇ are independently selected from:
- R is independently selected from hydrogen, Cl-C6 alkyl, 2,2,2- trifluoroethyl, benzyl and aryl;
- R 9 is independently selected from C1-C6 alkyl and aryl
- Rla and Rlc are independently selected from: hydrogen, R80-, -N(R8)2, F, C3-C10 cycloalkyl or C1-C6 alkyl;
- Rib is independently selected from: a) hydrogen, b) aryl, heterocycle or C3-C10 cycloalkyl, c) C1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, R 8 0-, or
- R 2a and R 2 b' are independently selected from selected from: H; Cl-
- R3a and R3b are independently selected from: a) hydrogen, b) unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, unsubstituted or substituted C3-C10 cycloalkyl, unsubstituted or substituted C 2 -C6 alkenyl, C2- C6 alkynyl, halogen, C1-C6 perfluoroalkyl, R9 ⁇ -,
- R*5a and R*5b are independently hydrogen, ethyl, cyclopropyl or methyl
- R6 and R ⁇ are independently selected from: H; Cl-4 alkyl, C3-6 cycloalkyl, aryl, heterocycle, unsubstituted or substituted with one or two: a) Cl-4 alkoxy, b) halogen, or c) substituted or unsubstituted aryl or substituted or unsubstituted heterocycle;
- R8 is independently selected from hydrogen, Cl-C alkyl, 2,2,2- trifluoroethyl, benzyl and aryl;
- R 9 is independently selected from C1-C6 alkyl and aryl
- a 1 is selected from: a bond, -C(O)-, O, -N(R8)-, or -S(0) m ;
- n 0, 1 or 2; provided that n is not 0 if Al is a bond, O,
- p is 1, 2 or 3
- q is 0, 1 or 2, provided that q is not 0 or 1 if X is O
- u is independently 0 or 1;
- the compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention.
- any variable e.g. aryl, heterocycle, Rla, R4 etc.
- its definition on each occurence is independent at every other occurence.
- combinations of substituents/or variables are permissible only if such combinations result in stable compounds.
- alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; “alkoxy” represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge.
- Halogen or “halo” as used herein means fluoro, chloro, bromo and iodo.
- aryl is intended to mean any stable monocyclic, bicyclic or tricyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic.
- monocyclic and bicyclic aryl elements include phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl.
- tricyclic aryl elements include 10,11- dihydro-5H-dibenzo[a,d]cyclohepten-5-yl (which is also known as dibenzylsuberyl), 9-fluorenyl and 9,10-dihydroanthracen-9-yl.
- "aryl” is a monocyclic or bicyclic carbon ring.
- heterocycle or heterocyclic represents a stable 5- to 7-membered monocyclic or stable 8- to 11- membered bicyclic heterocyclic ring or stable 13- to 15-membered tricyclic heterocyclic ring, which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
- the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
- Examples of monocyclic and bicyclic heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl,
- tricyclic heterocyclic elements include, but are not limited to, 6,l l-dihydro-5H- benzo[5,6]cyclohepta[l,2-b]pyridine, 9,10-dihydro-4H-3-thia- benzo[f]azulen-4-yl and 9-xanthenyl.
- the 6,11 -dihydro-5H- benzo[5,6]cyclohepta[l,2-b]pyridine moiety has the following structure:
- heterocyclic is a monocyclic or bicyclic moiety.
- heteroaryl is intended to mean any stable monocyclic, bicyclic or tricyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic and wherein from one to four carbon atoms are replaced by heteroatoms selected from the group consisting of N, O, and S.
- Examples of monocyclic and bicyclic heteroaryl elements include, but are not limited to, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, pyridyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrroly
- tricyclic heteroaryl elements include, but are not limited to, 6,ll-dihydro-5H- benzo[5,6]cyclohepta[l,2-b]pyridine.
- heteroaryl is a monocyclic or bicyclic moiety.
- substituted aryl As used herein, the terms “substituted aryl”, “substituted heterocycle” and “substituted cycloalkyl” are intended to include the cyclic group containing from 1 to 3 substitutents in addition to the point of attachment to the rest of the compound.
- Such substitutents are preferably selected from the group which includes but is not limited to F, Cl, Br, CF3, NH2, N(Cl-C6 alkyl) 2 , N ⁇ 2, CN, (C1-C6 alkyl)0-, - OH, (C1-C6 alkyl)S(0)m-, (Cl-C6 alkyl)C(0)NH-, H 2 N-C(NH)-, (Cl- C6 alkyl)C(O)-, (Ci-C6 alkyl)OC(O)-, N3,(Cl-C6 alkyl)OC(0)NH- and C1-C20 alkyl.
- cyclic amine moieties are formed.
- examples of such cyclic moieties include, but are not limited to:
- Such cyclic moieties may optionally include another heteroatom(s).
- heteroatom-containing cyclic amine moieties include, but are not limited to:
- R 2 , R , R4 etc. indicate that the indicated bond may be attached to any of the substitutable ring carbon or nitrogen atoms.
- Rla and Rib are independently selected from: hydrogen, -N(R8) 2 , R8c(0)NR8- or C1-C6 alkyl which is unsubstituted or substituted by -N(R8) 2 , R8Q- or R8C(0)NR -.
- R 2 a is selected from:H;
- R 2 b' and R 2 b" are independently selected from selected from: H or C1-C6 alkyl.
- R3a and R3b are independently selected from: hydrogen, C1-C6 perfluoroalkyl, F, Cl, Br, R80-, R 9 S(0) m -, CN, R8C(0)-, -N(R8)2 and C1-C6 alkyl.
- R4 is selected from: hydrogen, perfluoroalkyl, F, Cl, Br, R80-, R 9 S(0)m-, CN, N ⁇ 2, R 8 2N- C(NR8)-, R8C(0)-, N3, -N(R8)2, R9 ⁇ C(0)NR8- and C1-C6 alkyl.
- R-5 is hydrogen or C1-C6 alkyl.
- R is selected from H, C1-C6 alkyl and benzyl.
- Al and A 2 are independently selected from: a bond, -C(0)NR8-, -NR8C(0)-, O, -N(R8)-, -S(0)2N(R8)- and-
- V is selected from hydrogen, heterocycle and aryl.
- W is imidazolyl.
- n, p and r are independently 0, 1, or 2. More preferably, r is 1.
- t is 1.
- u is independently 0 or 1. Most preferably, u is 1.
- the pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed, e.g., from non-toxic inorganic or organic acids.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like: and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.
- any substituent or variable e.g., Rla, Z, n, etc.
- - N(R8)2 represents -NH2, -NHCH3, -NHC2H5, etc.
- substituents and substitution pattems on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials.
- the pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention
- SUBST ⁇ UTE SHEET (RULE 26) which contain a basic moiety by conventional chemical methods.
- the salts are prepared either by ion exchange chromatography or by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents.
- Scheme 1 illustrates the synthesis of 1,2,3,4- tetrahydroisoquinolines essentially according to the method of Stokker in Tetrahedron Letts., 1996, 37, 5453.
- phenethylamines such as
- trifluoroacetate 2 may be converted to the corresponding trifluoroacetate 2 using, for example, trifluoroacetic anhydride and an organic base such as triethylamine in a suitable solvent such as dichloromethane.
- Compound 8 may also be obtained from 5 using the well-known Bischler-Napieralski reaction. Reduction of the imine of 8 to 9 may be done with a reducing agent such as sodium borohydride in an alcoholic solvent (e.g. methanol) or, alternatively, asymmetric hydrogenation processes may be employed to give 9 in optically enriched form. Intermediate 9 may be coupled with a suitably substituted acid using standard amide bond formation methods to yield the instant compound 10.
- Scheme 3 illustrates reactions wherein the preferred 4- cyanobenzylimidazolyl moiety is incorporated into the instant compounds.
- Schemes 4-5 illustrate the syntheses of 1,2,3,4- tetrahydroisoquinolines of the instant invention wherein the "X" moiety is other than an alkyl bridge.
- the reactions illustrated therein show the incorporation of sidechains which comprise the preferred 4- cyanobenzylimidazolyl moiety. It is understood that a person of ordinary skill in the art could readily modify such reaction sequences by using appropriate protecting groups and reagents well known to one skilled in the art to provide other compounds of the instant invention.
- Scheme 4 illustrates the syntheses of compounds of the instant invention wherein "X" is -S-.
- the intermediate aldehyde 11 is reduced to the alcohol 12, activated and treated with a suitable thioacetate to provide the thioester 13.
- the thiol is then generated and alkylated with a suitable ester containing reagent, such as bromoacetic acid to provide intermediate 14.
- a suitable ester containing reagent such as bromoacetic acid
- Reduction of the ester moiety, followed by oxidation provides the corresponding aldehyde, which can be utilized to reductively alkylate the suitably substituted 1,2,3,4- tetrahydroisoquinoline to provide the instant compound 15.
- Scheme 5 illustrates the syntheses of compounds of the instant invention wherein "X" is -0-.
- a dihydroxyalkane such as ethylene glycol
- Intermediate 16 can be utilized to reductively alkylate the suitably substituted 1,2,3,4-tetrahydroisoquinoline and the sidechain deprotected.
- Intermediate 17 can then be alkylated with a suitable reagent to provide the instant compound 18 which incorporates the ether moiety.
- the reagent utilized in the reductive alkylation of the 1,2,3,4-tetrahydroisoquinoline may altematively incorporate a leaving group which may subsequently react with a blocked imidazolyl reagent, such as 19 to provide compounds of the instant invention wherein "X" is a bond and the preferred imidazolyl is attached to the alkyl bridge via one of the ring nitrogens, as shown in Scheme 6.
- Scheme 7 illustrates the syntheses of compounds of the instant invention comprising 3,4-dihydro-l(lH)-isoquinolinones, indoles and benzoimidazoles.
- R ,S a d ⁇ is V - A 1 (CR 1a 2 ) n A 2 (CR 1a 2 ) n (CR 1b 2 ) F or a protected precursor thereof;
- RSa. is R2a or a protected precusor thereof; and R$b- is R2b' ? R2b" or a protected precusor thereof; and
- R- is a "substituent" or a protected precusor thereof.
- the selectively protected intermediate 20 utilized in the synthesis illustrated in Scheme 8 can be reductively alkylated with a variety of aldehydes, such as 21.
- the aldehydes can be prepared by standard procedures, such as that described by O. P. Goel, U. Krolls, M. Stier and S. Kesten in Organic Syntheses. 1988, 67, 69-75.
- the reductive alkylation can be accomplished at pH 5-7 with a variety of reducing agents, such as sodium triacetoxyborohydride or sodium cyanoborohydride in a solvent such as dichloroethane, methanol or dimethylformamide.
- the ester product 22 can be deprotected with trifluoroacetic acid in methylene chloride to give the substituted diamine 23. That diamine may be isolated in the salt form, for example, as a
- the product diamine 23 can be further selectively protected and reductively alkylated with a second aldehyde to obtain an analogous tertiary amine. Altematively, the diamine 23 can be cyclized to obtain intermediates such as the dihydroimidazole 24 by procedures known in the literature. The ester 24 can then be utilized in a reaction such as illustrated in Scheme 3 hereinabove.
- Scheme 9 illustrates a general preparation of aralkyl imidazolyl intermediates 31 that can be utilized in reactions such as illustrated in Scheme 3.
- imidazole acetic acid 27 can be converted to the protected acetate 29 by standard procedures, and 29 can be first reacted with an alkyl halide, then treated with refluxing methanol to provide the regiospecifically alkylated imidazole acetic acid ester 30.
- Hydrolysis provides the acetic acid 31.
- Schemes 10-13 illustrate syntheses of suitably substituted alkanols useful in the syntheses of the instant compounds wherein the variable W is present as a pyridyl moiety.
- Scheme 15 illustrates synthesis of an instant compound wherein a non-hydrogen R ⁇ b i s incorporated in the instant compound.
- a readily available 4-substituted imidazole 37 may be selectively iodinated to provide the 5-iodoimidazole 38. That imidazole may then be protected and coupled to a suitably substituted benzyl moiety to provide intermediate 39. Intermediate 39 can then undergo the alkylation reactions that were described hereinabove.
- Al(CR a 2)nA (CRl a 2)n linker is oxygen may be synthesized by methods known in the art, for example as shown in Scheme 16.
- the suitably substituted phenol 41 may be reacted with methyl N- (cyano)methanimidate to provide the 4-phenoxy imidazole 42.
- the intermediate 43 can undergo alkylation reactions as described for the benzylimidazoles hereinabove.
- the instant compounds are useful as pharmaceutical agents for mammals, especially for humans. These compounds may be administered to patients for use in the treatment of cancer.
- Examples of the type of cancer which may be treated with the compounds of this invention include, but are not limited to, colorectal carcinoma, exocrine pancreatic carcinoma, myeloid leukemias and neurological tumors. Such tumors may arise by mutations in the ras genes themselves, mutations in the proteins that can regulate Ras activity (i.e., neurofibromin (NF-1), neu, ser, abl, lck, fyn) or by other mechanisms.
- the compounds of the instant invention inhibit farnesyl- protein transferase and the famesylation of the oncogene protein Ras.
- the instant compounds may also inhibit tumor angiogenesis, thereby affecting the growth of tumors (J. Rak et al. Cancer Research, 55:4575- 4580 (1995)). Such anti-angiogenesis properties of the instant compounds may also be useful in the treatment of certain forms of blindness related to retinal vascularization.
- the compounds of this invention are also useful for inhibiting other proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes (i.e., the Ras gene itself is not activated by mutation to an oncogenic form) with said inhibition being accomplished by the administration of an effective amount of the compounds of the invention to a mammal in need of such treatment.
- the compounds are useful in the treatment of neurofibromatosis, which is a benign proliferative disorder.
- the instant compounds may also be useful in the treatment of certain viral infections, in particular in the treatment of hepatitis delta and related viruses (J.S. Glenn et al. Science, 256: 1331-1333 (1992).
- the compounds of the instant invention are also useful in the prevention of restenosis after percutaneous transluminal coronary angioplasty by inhibiting neointimal formation (C. Indolfi et al. Nature medicine, 1:541-545(1995).
- the instant compounds may also be useful in the treatment and prevention of polycystic kidney disease (D.L. Schaffner et al. American Journal of Pathology, 142:1051-1060 (1993) and B. Cowley, Jr. et s ⁇ .FASEB Journal, 2: A3160 (1988)).
- the instant compounds may also be useful for the treatment of fungal infections.
- the compounds of this instant invention are selective inhibitors of famesyl- protein transferase.
- a compound is considered a selective inhibitor of famesyl-protein transferase, for example, when its in vitro famesyl- protein transferase inhibitory activity, as assessed by the assay described in Example 41, is at least 100 times greater than the in vitro activity of the same compound against geranylgeranyl-protein transferase-type I in the assay described in Example 42.
- a selective compound exhibits at least 1000 times greater activity against one of the enzymatic activities when comparing geranylgeranyl-protein transferase-type I inhibition and farnesyl-protein transferase inhibition.
- the compounds of this instant invention are dual inhibitors of farnesyl- protein transferase and geranylgeranyl-protein transferase type I. Such a dual inhibitor will exhibit certain characteristics when assessed in in vitro assays, which are dependent on the type of assay employed.
- the dual inhibitor compound has an in vitro inhibitory activity (IC50) that is less than about 12 ⁇ M against K4B-Ras dependent activation of MAP kinases in cells. More preferably, the dual inhibitor compound has an in vitro inhibitory activity (IC50) against K4B-Ras dependent activation of MAP kinases in cells which is more than about 5 times lower than the inhibitory activity (IC50) against Myr-Ras dependent activation of MAP kinases in cells.
- IC50 in vitro inhibitory activity
- the dual inhibitor compound has an inhibitory activity (IC50) that is less than about 10 nM against H-Ras dependent activation of MAP kinases in cells.
- IC50 inhibitory activity
- the dual inhibitor compound has an in vitro inhibitory activity (IC50) that is less than about 5 ⁇ M against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAXG motif by geranylgeranyl-protein transferase type I in the presence of a modulating anion.
- the dual inhibitor compound has an in vitro inhibitory activity (IC50) that is less than about 1 ⁇ M against transfer of a geranylgeranyl residue to a protein or peptide substrate comprising a CAAXG motif by geranylgeranyl- protein transferase type I in the presence of a modulating anion.
- IC50 in vitro inhibitory activity
- the dual inhibitor compound has an in vitro inhibitory activity (IC50) in the in vitro assay as described in Example 41 that is less than about 1 ⁇ M against transfer of a famesyl residue to a protein or peptide substrate, comprising a CAAX-F motif, by farnesyl-protein transferase.
- the dual inhibitor compound has an in vitro inhibitory activity (IC50) that is less than about lOOnM against transfer of a farnesyl residue to a protein or peptide substrate, comprising a CAAX* 7 motif, by farnesyl-protein transferase. Also preferably, the dual inhibitor compound has an in vitro inhibitory activity (IC50) in the in vitro assay as described in Example 44, that is less than about 100 nM against the anchorage independent growth of H- ras-transformed mammalian fibroblasts.
- IC50 in vitro inhibitory activity
- the protein or peptide substrate utilized in the instant assay may incorporate any CAAX motif that is geranylgeranylated by GGTase-I.
- CAAX will refer to such motifs that may be geranylgeranylated by GGTase-I. It is understood that some of the
- CAAX containing protein or peptide substrates may also be farnesylated by farnesyl-protein transferase.
- farnesyl-protein transferase a protein or peptide substrates
- CAAX motifs include (the corresponding human protein is in parentheses): CVIM (K4B-Ras) (SEQ.ID.NO.: 1), CVLL (mutated H- Ras) (SEQ.ID.NO.: 2), CVVM (N-Ras) (SEQ.ID.NO.: 3), CUM (K4A- Ras) (SEQ.ID.NO.: 4), CLLL (Rap-IA) (SEQ.ID.NO.: 5), CQLL (Rap- IB) (SEQ.ID.NO.: 6), CSIM (SEQ.ID.NO.: 7), CAIM (SEQ.ID.NO.: 8), CKVL (SEQ.ID.NO.: 9) and CLIM (PFX) (SEQ.ID.NO.: 10).
- the CAAX motif is
- CAAX is used to designate a protein or peptide substrate that incorporates four amino acid C- terminus motif that is farnesylated by famesyl-protein transferase. It is
- CAAX containing protein or peptide substrates may also be geranylgeranylated by GGTase-I.
- GGTase-I geranylgeranylated by GGTase-I.
- CAAX motifs include (the corresponding human protein is in parentheses): CVLS (H-ras) (SEQ.ID.NO.: 11), CVIM (K4B-Ras) (SEQ.ID.NO.: 1) and CVVM (N-Ras) (SEQ.ID.NO.: 3).
- the compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice.
- the compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
- a chemotherapeutic compound according to this invention the selected compound may be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension.
- carriers which are commonly used include lactose and com starch, and lubricating agents, such as magnesium stearate, are commonly added.
- useful diluents include lactose and dried com starch.
- aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added.
- sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered.
- the total concentration of solutes should be controlled in order to render the preparation isotonic.
- the present invention also encompasses a pharmaceutical composition useful in the treatment of cancer, comprising the administration of a therapeutically effective amount of the compounds of this invention, with or without pharmaceutically acceptable carriers or diluents.
- suitable compositions of this invention include aqueous solutions comprising compounds of this invention and pharmacologically acceptable carriers, e.g., saline, at a pH level, e.g., 7.4.
- the solutions may be introduced into a patient's intramuscular blood-stream by local bolus injection.
- composition is intended to encompass a product comprising the specified ingredients in the specific amounts, as well as any product which results, directly or indirectly, from combination of the specific ingredients in the specified amounts.
- the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.
- a suitable amount of compound is administered to a mammal undergoing treatment for cancer.
- Administration occurs in an amount between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 40 mg/kg of body weight per day.
- the compounds of the instant invention are also useful as a component in an assay to rapidly determine the presence and quantity of famesyl-protein transferase (FPTase) in a composition.
- FPTase famesyl-protein transferase
- the composition to be tested may be divided and the two portions contacted with mixtures which comprise a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and farnesyl pyrophosphate and, in one of the mixtures, a compound of the instant invention.
- the chemical content of the assay mixtures may be determined by well known immunological, radiochemical or chromatographic techniques. Because the compounds of the instant invention are selective inhibitors of FPTase, absence or quantitative reduction of the amount of substrate in the assay mixture without the compound of the instant invention relative to the presence of the unchanged substrate in the assay containing the instant compound is indicative of the presence of FPTase in the composition to be tested. It would be readily apparent to one of ordinary skill in the art that such an assay as described above would be useful in identifying tissue samples which contain famesyl-protein transferase and quantitating the enzyme.
- potent inhibitor compounds of the instant invention may be used in an active site titration assay to determine the quantity of enzyme in the sample.
- a series of samples composed of aliquots of a tissue extract containing an unknown amount of famesyl-protein transferase, an excess amount of a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and farnesyl pyrophosphate are incubated for an appropriate period of time in the presence of varying concentrations of a compound of the instant invention.
- concentration of a sufficiently potent inhibitor i.e., one that has a Ki substantially smaller than the concentration of enzyme in the assay vessel
- concentration of a sufficiently potent inhibitor i.e., one that has a Ki substantially smaller than the concentration of enzyme in the assay vessel
- Step 1 Preparation of l-triphenylmethyl-4-(hydroxymethyl)- imidazole To a solution of 4-(hydroxymethyl)imidazole hydrochloride (35 g) in 250 mL of dry DMF at room temperature was added triethylamine (90.6 mL). A white solid precipitated from the solution. Chlorotriphenylmethane (76.1 g) in 500 mL of DMF was added dropwise. The reaction mixture was stirred for 20 hours, poured over ice, filtered, and washed with ice water. The resulting product was slurried with cold dioxane, filtered, and dried in vacuo to provide the title compound as a white solid which was sufficiently pure for use in the next step.
- Step 2 Preparation of l-triphenylmethyl-4-(acetoxymethyl)- imidazole
- Step 4 Preparation of l-(4-cyanobenzyl)-5-(hydroxymethyl)- imidazole
- Step 5 Preparation of l-(4-cyanobenzyl)-5-imidazole- carboxaldehyde
- Step 6 Preparation of 7-bromo-2-(l-(4-cyanobenzyl)-5- imidazolylmethyl)- 1.2.3.4-tetrahydroisoquinoline
- Step 1 3(S)-Carboethoxy- 1.2.3.4-tetrahydroisoquinoline
- the title compound was obtained from N-Boc-L-1,2,3,4- tetrahydroisoquinoline-3-carboxylic acid (Bachem) using standard amino acid chemical procedures.
- Step 2 3(S)-Carboethoxy-2-(l-(4-cyanobenzyl)imidazol-5- ylmethyl)- 1.2.3.4-tetrahydroisoquinoline dihydrochloride salt
- Step 2 3 (R)-Carboethoxy-2- ( 1 - (4-cy anobenzyl)imidazol-5 - ylmethyl)- 1 ,2,3,4-tetrahydroisoquinoline dihydrochloride salt
- Step 1 Preparation of 7-amino-2-trifluoroacetoxy- 1,2,3,4- tetrahydroisoquinoline
- a solution of 7-nitro-2-trifluoroacetoxy- 1,2,3,4- tetrahydroisoquinoline (Stokker, Tetrahedron Letts., 1996, 37, 5453; 3.64 g, 13.3 mmol) in 100 mL EtOH at room temperature was was purged with argon and 10% palladium on carbon (300 mg) added. The mixture was then stirred under an atmosphere of hydrogen gas for 2 h. then filtered and the solvent removed in vacuo to yield a white solid which was sufficiently pure for use in the next step.
- Step 2 Preparation of 7-iodo-2-trifluoroacetoxy- 1,2,3,4- tetrahydroisoquinoline
- the aniline prepared above (3.34 g, 13.7 mmol) was suspended in 30 mL 3N HCI, cooled to 0°C and treated with a solution of NaN02 (1-04 g, 15.1 mmol) in 7 mL H2 ⁇ . After 30 minutes, a solution of KI (6.8 g, 41.1 mmol) in 10 mL H2O was added to the reaction mixture and stirring was continued for 45 minutes. The mixture was partitioned between CHCI3 and water, the organic layer was washed with aqueous NaHS ⁇ 3 then brine, dried and evaporated. Chromatography of the residue (hexane/EtOAc 5: 1) afforded the title compound as a colorless oil.
- Step 4 7-iodo-2-(l-(4-cyanobenzyl)-5-imidazolylmethyl)-l,2,3,4- tetrahydroisoquinoline bis hydrochloride salt
- Step 1 Preparation of 5-(4-cyanobenzyl)-2-trifluoroacetoxy- 1.2.3.4-tetrahydroisoquinoline
- Step 1 Preparation of 5-(2-(3-tolyl)vinyl)-2-trifluoroacetoxy- 1.2.3.4-tetrahydroisoquinoline
- Step 2 Preparation of 5-(3-tolyl)vinyl)- 1,2,3,4- tetrahydroisoquinoline
- Step 1 Preparation of 5-(3-tolyl)ethyl)-l,2,3,4- tetrahydroisoquinoline
- the stilbene from Example 13, Step 2 (242 mg, 1 mmol) was hydrogenated in 10 mL EtOH with 50 mg 10% palladium on carbon and hydrogen gas (balloon). Filtration through celite and removal of the solvent gave the title compound.
- Step 2 5-(3-Tolyl)ethyl)-2-(l-(4-cyanobenzyl)-5- imidazolylmethyl)- 1.23.4-tetrahydroisoquinoline
- Step 1 Preparation of 7-bromo-N-Boc- 1,2,3,4- tetrahydroisoquinoline
- Step 2 Preparation of 7-phenyl-N-Boc- 1,2,3, 4- tetrahydroisoquinoline
- Step 4 Preparation of 7-phenyl-2-(l-(4-cyanobenzyl)-5- imidazolylmethyl)- 1.2.3.4-tetrahydroisoquinoline Following the procedure described for Example 1, Step 6 but using 7-phenyl-l,2,3,4-tetrahydroisoquinoline the title compound was obtained as a white solid. Analysis for C27H24N4
- Step 1 Preparation of 7 -bromo-N-Boc- 1,2,3,4- tetrahydroisoquinoline
- Step 2 Preparation of 7-(2-tolyl)-N-Boc-l, 2,3,4- tetrahydroisoquinoline
- Step 4 Preparation of 7-(2-tolyl)-2-(l-(4-cyanobenzyl)-5- imidazolylmethyl)- 1.2.3.4-tetrahydroisoquinoline
- N-Boc-L-l,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Bachem) was coupled with 2,3-dimethyl aniline using standard peptide coupling procedures.
- the product was deprotected using TFA in CH2CI2 to give the title compound.
- Step 2 Preparation of N-(2,3-dimethyl ⁇ henyl)-2-(l-(4- cyanobenzyl)-5-imidazolylmethyl)-l,2,3,4- tetrahydroisoquinoline-3(S)-carboxamide bis trifluoroacetate salt
- Step 1 Preparation of N-(3-chlorobenzyl) 2-Boc- 1,2,3,4- tetrahydroisoquinoline-3(S)-carboxamide
- N-Boc-L- 1 ,2,3 ,4-tetrahydroisoquinoline-3-carboxylic acid (Bachem) was coupled with 3-chlorobenzylamine using standard peptide coupling procedures to give the title compound.
- Step 3 Preparation of N-(3-chlorobenzyl),N-Methyl 2-(l-(4- cyanobenzyl)-5-imidazolylmethyl)- 1 ,2,3,4- tetrahydroisoquinoline-3(S)-carboxamide bis trifluoroacetate salt Following the procedure described for Example 17 but using N-methyl 2-Boc-l,2,3,4-tetrahydroisoquinoline-3(S)- carboxamide, the title compound was obtained as a white solid.
- Step 1 Preparation of 2-Boc-3(S)-carboethoxy-7-hydroxy- 1,2,3,4- tetrahydroisoquinoline
- Step 2 Preparation of 2-Boc-3(S)-carboethoxy-7- trifluoromethylsulfonyloxy- 1.2.3.4-tetrahydroisoquinoline
- Step 4 Preparation of 3(S)-carboethoxy-7-phenyl- 1,2,3,4- tetrahydroisoquinoline hydrochloride
- Step 5 Preparation of 3(S)-carboethoxy-7-phenyl-2-(l-(4- cyanobenzyl)-5-imidazolylmethyl)- 1 ,2,3 ,4- tetrahydroisoquinoline dihydrochloride salt Following the procedure described for Example 1, Step 6 but using the product from Step 4 the title compound was obtained as a white solid.
- Step 2 Preparation of 1 -n-buty 1-7 -bromo- 3.4-dihydroisoquinoline
- Step 3 Preparation of l(R,S)-n-butyl-7-bromo- 1,2,3,4- tetrahydroisoquinoline
- Step 4 Preparation of l(R,S)-n-butyl-7-bromo-2-(l-(4- cyanobenzyl)-5-imidazolylmethyl)- 1 ,2,3,4- tetrahydroisoquinoline dihydrochloride salt
- Step 2 Preparation of l-(l-(4-cyanobenzyl)-5-imidazolylmethyl) indole
- Step 1 Preparation of 4-phenylindole Following the procedure described for Example 21, Steps 2 and 3, 5-hydroxyindole (Aldrich) was converted into the title compound.
- Step 1 Preparation of 6-Bromo-3.4-dihydro-l(TH)-isoquinolinone
- 5-bromo-l-indanone Aldrich
- H2SO4 38 mL
- NaN3 NaN3 portionwise over 20 minutes.
- the mixture was diluted EtOAc, washed with water then brine, dried and evaporated. Chromatography of the residue (silica gel; hexane/EtOAc 1:1) afforded the title compound as a solid.
- Step 2 Preparation of 6-bromo-2-(l-(4-cyanobenzyl)-5- imidazolylmethyl)-3,4-dihydro- 1 (lH)-isoquinolinone hydrochloride salt
- Step 2 Preparation of 6-Bromo-2-(l-(4-cyanobenzyl)-5- imidazolylmethyl)- 1.2.3.4-tetrahydroisoquinoline Following the procedure described for Example 1, Step 6 but using 6-bromo-l,2,3,4-tetrahydroisoquinoline from Step 1 the title compound was obtained. Analysis for C2lHl9N4Br Calcd. C, 61.92; H, 4.70; N, 13.76 found C, 61.59; H, 4.65; N, 13.49
- Step 2 Preparation of 1 -(triphenylmethyl)- 1 H-imidazol-4-ylacetic acid methyl ester
- Step 3 Preparation of [l-(4-cyanobenzyl)-lH-imidazol-5-yl]acetic acid methyl ester
- 1 -(triphenylmethyl)- lH-imidazol-4- ylacetic acid methyl ester 8.00 g, 20.9 mmol
- bromo-p-toluonitrile 4.10g, 20.92 mmol
- the reaction was cooled to room temperature and the resulting imidazolium salt (white precipitate) was collected by filtration. The filtrate was heated at 55°C for 18 h.
- Step 5 Preparation 7-bromo-2-(l-(4-cyanobenzyl)-5- imidazolylacetyl)- 1 ,2,3,4-tetrahydroisoquinoline hydrochloride
- the acid from Step 4 0.575 g, 2 mmol
- 7-bromo- 1,2,3,4- tetrahydroisoquinoline (0.424 g, 2 mmol) and HOBT 0.297 g, 2.2 mmol
- DMF 15 mL
- NMM (0.44 mL, 4 mmol
- EDC 0.46 g, 2.4 mmol
- Step 1 Preparation of 4-(3-bromo-phenyl)-4,5,6,7-tetrahydro-3H- imidazor4.5-clpyri.dine Histamine dihydrochloride (3.68 g, 0.02 mol), KOH (3.36 g, 0.06 mol), and 3-bromobenzaldehyde were dissolved in H 2 0 (250 mL) and EtOH(100 mL). The reaction mixture was heated for 24 h at
- Step 2 Preparation of 4-(3-bromo-phenyl)-6,7-dihydro-4H- imidazo[4,5-c]pyridine-l,5-dicarboxylic acid di-tert-butyl ester 4-(3-Bromo-phenyl)-4,5,6,7-tetrahydro-3H-imidazo[4,5- yridine (1.0 g, 3.6 mmol), Boc 2 0 (1.74 g, 7.9 mmol), and Et 3 N (1.1 mL, 7.9 mmol) were dissolved in CH 2 C1 2 (35 mL) and stirred overnight at room temperature under Ar. The reaction was washed with H 2 0, brine, and dried (N- ⁇ SO . Filtration, concentration, and silica gel chromatography (1:6 EtOAc/hexane) yielded the title compound.
- Step 3 Preparation of 4-(3-bromo-phenyl)-l,4,6,7-tetrahydro- imidazor4.5-c]pyridine-5-carboxylic acid tert-butyl ester 4-(3-Bromophenyl)-6,7-dihydro-4H- imidazo[4,5- c]pyridine-l,5-dicarboxylic acid di-tert-butyl ester (0.879 g, 1.83 mmol) and Zn(CN) 2 (0.323 g, 2.75 mmol) were stirred in anh. DMF (30 mL) at 80°C under Ar for 72 h. The solution was concentrated in vacuo, partitioned between CHC1 3 and sat. NaHC0 3 soln, dried (MgS0 4 ), filtered, and concentrated to yield the title compound without further purification.
- Step 4 Preparation of 4-(3-bromo-phenyl)-l-[3-(4-cyano-benzyl)- H-imidazol-4-ylmethyl]- 1 ,4,6,7-tetrahydro-imidazo[4,5- clpyridine-5-carboxylic acid tert-butyl ester 4-(3-Bromo-phenyl)- 1 ,4,6,7-tetrahydro-imidazo[4,5- c]pyridine-5-carboxylic acid t ⁇ rz'-butyl ester (0.160 g, 0.422 mmol) and 5-(chloromethyl)-l-(4-cyanobenzyl)-imidazole hydrochloride, as described in Example 26, Step 1, (0.119 g, 0.444 mmol), were dissolved in DMF (6 mL).
- Step 5 Preparation of 4- ⁇ 5-[4-(3-bromophenyl)-4,5,6,7- tetrahydroimidazo[4,5-c]pyridin- 1 -ylmethyljimidazol- 1- . ylmethyl ⁇ -benzonitrile
- Step 1 Preparation of N-(2-phenethyl) 2-(3-methoxyphenethyl) amine
- Step 2 Preparation of l-(2-phenethyl)-6-methoxy-3,4- dihydroisoquinoline
- Step 3 Preparation of l(R,S)-(2-phenethyl)-6-methoxy-l,2,3,4- tetrahydroisoquinoline
- Step 4 Preparation of l(R,S)-(2-Phenethyl)-6-methoxy-2-(l-(4- cy anobenzyl)-5-imidazolylmethyl)- 1,2,3 ,4- tetrahydroisoquinoline
- Bovine FPTase was assayed in a volume of 100 ml containing 100 mM N-(2- hydroxy ethyl) piperazine-N'-(2-ethane sulfonic acid) (HEPES), pH 7.4, 5 mM MgCl2, 5 mM dithiothreitol (DTT), 100 mM [3H]-farnesyl diphosphate ([3HJ-FPP; 740 CBq/mmol, New England Nuclear), 650 nM Ras-CVLS and 10 mg/ml FPTase at 31°C for 60 min. Reactions were initiated with FPTase and stopped with 1 ml of 1.0 M HCL in ethanol.
- Precipitates were collected onto filter-mats using a TomTec Mach II cell harvestor, washed with 100% ethanol, dried and counted in an LKB b- plate counter.
- the assay was linear with respect to both substrates, FPTase levels and time; less than 10% of the [3H]-FPP was utilized during the reaction period.
- Purified compounds were dissolved in 100% dimethyl sulfoxide (DMSO) and were diluted 20-fold into the assay. Percentage inhibition is measured by the amount of incorporation of radioactivity in the presence of the test compound when compared to the amount of incorporation in the absence of the test compound.
- DMSO dimethyl sulfoxide
- Human FPTase was prepared as described by Omer et al. , Biochemistry 32:5167-5176 (1993). Human FPTase activity was assayed as described above with the exception that 0.1% (w/v) polyethylene gly col 20,000, 10 mM ZnCl2 and 100 nM Ras-CVIM were added to the reaction mixture. Reactions were performed for 30 min., stopped with 100 ml of 30% (v/v) trichloroacetic acid (TCA) in ethanol and processed as described above for the bovine enzyme.
- TCA trichloroacetic acid
- the modified geranylgeranyl-protein transferase inhibition assay is carried out at room temperature.
- a typical reaction contains (in a final volume of 50 mL): [ 3 H] geranylgeranyl diphosphate, biotinylated Ras peptide, 50 mM HEPES, pH 7.5, a modulating anion (for example 10 mM glycerophosphate or 5mM ATP), 5 mM MgCl 2 , 10 mM ZnCl 2 ,
- the GGTase-type I enzyme employed in the assay is prepared as described in U.S. Pat. No. 5,470,832, incorporated by reference.
- the Ras peptide is derived from the K4B-Ras protein and has the following sequence: biotinyl- GKKKKKKSKTKCVIM (single amino acid code) (SEQ.ID.NO.: 13).
- Reactions are initiated by the addition of GGTase and stopped at timed intervals (typically 15 min) by the addition of 200 mL of a 3 mg/mL suspension of streptavidin SPA beads (Scintillation Proximity Assay beads, Amersham) in 0.2 M sodium phosphate, pH 4, containing 50 mM EDTA, and 0.5% BSA. The quenched reactions are allowed to stand for 2 hours before analysis on a Packard TopCount scintillation counter.
- assays are mn as described above, except inhibitors are prepared as concentrated solutions in 100% dimethyl sulfoxide and then diluted 25-fold into the enzyme assay mixture.
- IC 50 values are determined with Ras peptide near KM concentrations. Enzyme and nonsaturating substrate conditions for inhibitor IC 50 determinations are as follows: 75 pM GGTase-I, 1.6 mM Ras peptide, 100 nM geranylgeranyl diphosphate. EXAMPLE 43
- the cell lines used in this assay consist of either Ratl or NIH3T3 cells transformed by either viral H-ras; an N-ras chimeric gene in which the C-terminal hypervariable region of viral-H-ras was substituted with the corresponding region from the N-ras gene; or ras-CVLL, a viral-H-ras mutant in which the C-terminal exon encodes leucine instead of serine, making the encoded protein a substrate for geranylgeranylation by GGTase-I.
- the assay can also be performed using cell lines transformed with human H-ras, N-ras or K4B-ras.
- the assay is performed essentially as described in DeClue, J.E. et al., Cancer Research 51:712-717, (1991). Cells in 10 cm dishes at 50-75% confluency are treated with the test compound(s) (final concentration of solvent, methanol or dimethyl sulfoxide, is 0.1%). After 4 hours at 37°C, the cells are labelled in 3 ml methionine-free DMEM supplemented with 10% regular DMEM, 2% fetal bovine serum, 400 mCi[35S)methionine (1000 Ci/mmol) and test compound(s).
- lovastatin a compound that blocks Ras processing in cells by inhibiting the rate-limiting step in the isoprenoid biosynthetic pathway (Hancock, J.F. et al. Cell, 57: 1167 (1989); DeClue, J.E. et al. Cancer Res., 51:712 (1991); Sinensky, M. et al. /. Biol Chem., 265:19937 (1990)), serve as a positive control in this assay.
- the cells are lysed in 1 ml lysis buffer (1% NP40/20 mM HEPES, pH 7.5/5 mM MgCl2/lmM DTT/10 mg/ml aprotinen/2 mg/ml leupeptin/2 mg/ml antipain/0.5 mM PMSF) and the lysates cleared by centrifugation at 100,000 x g for 45 min.
- lysis buffer 1% NP40/20 mM HEPES, pH 7.5/5 mM MgCl2/lmM DTT/10 mg/ml aprotinen/2 mg/ml leupeptin/2 mg/ml antipain/0.5 mM PMSF
- the immunoprecipitates are washed four times with IP buffer (20 nM HEPES, pH 7.5/1 mM EDTA/1% Triton X-100.0.5% deoxycholate/0.1%/SDS/0.1 M NaCl) boiled in SDS-PAGE sample buffer and loaded on 13% acrylamide gels. When the dye front reached the bottom, the gel is fixed, soaked in Enlightening, dried and autoradiographed. The intensities of the bands corresponding to prenylated and nonprenylated Ras proteins are compared to determine the percent inhibition of prenyl transfer to protein.
- IP buffer 20 nM HEPES, pH 7.5/1 mM EDTA/1% Triton X-100.0.5% deoxycholate/0.1%/SDS/0.1 M NaCl
- SALSA Soft Agar-Like Surrogate Assay measures the inhibition of anchorage-independent growth by prenyl-transferase inhibitors. Only transformed cells are able to grow anchorage- independently in the SALSA format. Additionally, cells growing in the SALSA format grow in clumps, resembling the colonies formed in soft agar. SALSA may been used to measure the growth inhibition by prenyl-transferase inhibitors in a variety of transformed cell lines, including Ratl fibroblasts transformed with viral-H-ras (H-ras/ratl), as well as a panel of human tumor cell lines (HTL's).
- H-ras/ratl Ratl fibroblasts transformed with viral-H-ras
- HTL's human tumor cell lines
- SALSA is performed in 96-well plates that are coated with a thin film of the polymer, PolyHEMA (Poly(2-hydroxyethyl methacrylate)), which prevents cells from attaching to the plate.
- Ratl fibroblast cells transformed with v-Ha-ras (this cell line has been deposited in the ATCC on August 19, 1997 under the terms of the Budapest convention and has been given a designation of ATCC CRL 12387) are seeded at 5000 cells/well, grown for 4 hr, then vehicle or half-log dilutions of test compound (in either an 8 or 12 point titration) are added. The cells are then grown for 6 days at 37 degrees, without changing the growth media or adding fresh compound.
- cell growth is assessed via a colorimetric assay that measures the cleavage of the tetrazolium dye, MTT, to an insoluble purple formazan, a reaction dependent upon mitochondrial dehydrogenases.
- MTT tetrazolium dye
- SDS is added to 9% w/v to lyse the cells and solubilize the insoluble MTT-formazan.
- the amount of MTT metabolism is quantitated via spectrophotometric detection at 570 nM. Dose-inhibition curves and IC 50 's are determined.
- the SEAP reporter plasmid, pDSElOO was constructed by ligating a restriction fragment containing the SEAP coding sequence into the plasmid pCMV-RE-AKI.
- the SEAP gene is derived from the plasmid pSEAP2-Basic (Clontech, Palo Alto, CA).
- the plasmid pCMV- RE-AKI was constructed by Deborah Jones (Merck) and contains 5 sequential copies of the 'dyad symmetry response element' cloned upstream of a 'CAT-TATA' sequence derived from the cytomegalovims immediate early promoter.
- the plasmid also contains a bovine growth hormone poly-A sequence.
- the plasmid, pDSElOO was constmcted as follows. A restriction fragment encoding the SEAP coding sequence was cut out of the plasmid pSEAP2-Basic using the restriction enzymes EcoRI and Hpal. The ends of the linear DNA fragments were filled in with the Klenow fragment of E. coli DNA Polymerase I. The 'blunt ended' DNA containing the SEAP gene was isolated by electrophoresing the digest in an agarose gel and cutting out the 1694 base pair fragment. The vector plasmid pCMV-RE-AKI was linearized with the restriction enzyme B gill and the ends filled in with Klenow DNA Polymerase I.
- the SEAP DNA fragment was blunt end ligated into the pCMV-RE-AKI vector and the ligation products were transformed into DH5-alpha E. coli cells (Gibco-BRL). Transformants were screened for the proper insert and then mapped for restriction fragment orientation. Properly oriented recombinant constructs were sequenced across the cloning junctions to verify the correct sequence. The resulting plasmid contains the SEAP coding sequence downstream of the DSE and CAT-TATA promoter elements and upstream of the BGH poly-A sequence. Cloning of a Myristylated viral-H-ms expression plasmid
- a DNA fragment containing viral-H-ras can be PCRed from plasmid "H-l” (Ellis R. et al. J. Virol. 36, 408, 1980) using the following oligos.
- Antisense 5'CACATCTAGATCAGGACAGCACAGACTTGCAGC 3'. (SEQ.ID.NO.: 15)
- the sense strand oligo also optimizes the 'Kozak' translation initiation sequence immediately 5' to the ATG start site.
- cysteine 186 would be mutated to a serine by substituting a G residue for a C residue in the C-terminal antisense oligo.
- the PCR primer oligos introduce an Xhol site at the 5' end and a Xbal site at the 3 'end.
- the Xhol-Xbal fragment can be ligated into the mammalian expression plasmid pCI (Promega) cut with Xhol and Xbal. This results in a plasmid in which the recombinant myr- viral-H-ras gene is constitutively transcribed from the CMV promoter of the pCI vector.
- a viral-H-ras clone with a C-terminal sequence encoding the amino acids CVLL can be cloned from the plasmid "H-l" (Ellis R. et al. J. Virol. 36, 408, 1980) by PCR using the following oligos.
- Sense strand
- Antisense strand
- the sense strand oligo optimizes the 'Kozak' sequence and adds an Xhol site.
- the antisense strand mutates serine 189 to leucine and adds an
- the PCR fragment can be trimmed with Xhol and Xbal and ligated into the Xhol-Xbal cut vector pCI (Promega). This results in a plasmid in which the mutated viral-H-ras-CVLL gene is constitutively transcribed from the CMV promoter of the pCI vector.
- the human c-H-ras gene can be PCRed from a human cerebral cortex cDNA library (Clontech) using the following oligonucleotide primers.
- Antisense strand
- the primers will amplify a c-H-ras encoding DNA fragment with the primers contributing an optimized 'Kozak' translation start sequence, an EcoRI site at the N-terminus and a Sal I stite at the C-terminal end.
- the c-H-ras fragment can be ligated ligated into an EcoRI -Sal I cut mutagenesis vector p Alter- 1 (Promega). Mutation of glutamine-61 to a leucine can be accomplished using the manufacturer' s protocols and the following oligonucleotide:
- the mutated c-H-ras-Leu61 can be excised from the p Alter- 1 vector, using EcoRI and Sal I, and be directly ligated into the vector pCI (Promega) which has been digested with EcoRI and Sal I.
- the new recombinant plasmid will constitutively transcribe c-H-ras-Leu61 from the CMV promoter of the pCI vector.
- the human c-N-ras gene can be PCRed from a human cerebral cortex cDNA library (Clontech) using the following oligonucleotide primers.
- Antisense strand
- the primers will amplify a c-N-ras encoding DNA fragment with the primers contributing an optimized 'Kozak' translation start sequence, an
- the c-N-ras fragment can be ligated into an EcoRI -Sal I cut mutagenesis vector p Alter- 1 (Promega). Mutation of glycine- 12 to a valine can be accomplished using the manufacturer's protocols and the following oligonucleotide: 5'-GTTGGAGCAGTTGGTGTTGGG-3' (SEQ.ID.NO.: 23)
- the mutated c-N-r ⁇ s-Val-12 can be excised from the pAlter-1 vector, using EcoRI and Sal I, and be directly ligated into the vector pCI (Promega) which has been digested with EcoRI and Sal I.
- the new recombinant plasmid will constitutively transcribe c-N-r ⁇ s- Val- 12 from the CMV promoter of the pCI vector.
- the human c-K-r ⁇ s gene can be PCRed from a human cerebral cortex cDNA library (Clontech) using the following oligonucleotide primers.
- Antisense strand 5 ' -CTCTGTCGACGTATTTAC ATAATTAC ACACTTTGTC-3 ' (SEQ.ID.NO.: 25)
- the primers will amplify a c-K-r ⁇ s encoding DNA fragment with the primers contributing an optimized 'Kozak' translation start sequence, a Kpnl site at the N-terminus and a Sal I stite at the C-terminal end.
- the c-K-r ⁇ s fragment can be ligated into a Kpnl -Sal I cut mutagenesis vector p Alter- 1 (Promega). Mutation of cysteine- 12 to a valine can be accomplished using the manufacturer's protocols and the following oligonucleotide:
- the mutated c-K-ras-Val-12 can be excised from the p Alter- 1 vector, using Kpnl and Sal I, and be directly ligated into the vector pCI (Promega) which has been digested with Kpnl and Sal I.
- the new recombinant plasmid will constitutively transcribe c-K-ras-Val-12 from the CMV promoter of the pCI vector.
- Human C33A cells (human epitheial carcenoma - ATTC collection) are seeded in 10cm tissue culture plates in DMEM + 10% fetal calf semm + IX Pen/Strep + IX glutamine + IX NEAA. Cells are grown at 37°C in a 5% C02 atmosphere until they reach 50 -80% of conflunecy.
- transient transfection is performed by the CaP04 method (Sambrook et al., 1989).
- expression plasmids for H-ras, N-r ⁇ s, K-r ⁇ s, Myr-r ⁇ s or H-r ⁇ s-CVLL are co-precipitated with the DSE-SEAP reporter constmct.
- 600ml of CaCl 2 -DNA solution is added dropwise while vortexing to 600ml of 2X HBS buffer to give 1.2ml of precipitate solution (see recipes below). This is allowed to sit at room temperature for 20 to 30 minutes. While the precipitate is forming, the media on the C33A cells is replaced with DMEM (minus phenol red; Gibco cat.
- the cells are washed with PBS and trypsinized with 1ml of 0.05% trypsin.
- the 1 ml of trypsinized cells is diluted into 10ml of phenol red free DMEM + 0.2% charcoal stripped calf semm + IX (Pen Strep, Glutamine and NEAA ).
- Transfected cells are plated in a 96 well microtiter plate (100ml/ well) to which drug, diluted in media, has already been added in a volume of 100ml. The final volume per well is 200ml with each dmg concentration repeated in triplicate over a range of half-log steps.
- the heat treated media is assayed for alkaline phosphatase by a luminescence assay using the luminescence reagent CSPD® (Tropix, Bedford, Mass.).
- a volume of 50 ml media is combinRased with 200 ml of CSPD cocktail and incubated for 60 minutes at room temperature. Luminesence is monitored using an ML2200 microplate luminometer (Dynatech). Luminescence reflects the level of activation of the fos reporter construct stimulated by the transiently expressed protein.
- Rodent fibroblasts transformed with oncogenically mutated human Ha-r ⁇ s or Ki-r ⁇ s are injected subcutaneously into the left flank of 8-12 week old female nude mice (Harlan) on day 0.
- the mice in each oncogene group are randomly assigned to a vehicle, compound or combination treatment group. Animals are dosed subcutaneously starting on day 1 and daily for the duration of the experiment.
- the farnesyl-protein transferase inhibitor may be administered by a continuous infusion pump.
- Compound, compound combination or vehicle is delivered in a total volume of 0.1 ml. Tumors are excised and weighed when all of the vehicle-treated animals exhibited lesions of 0.5 - 1.0 cm in diameter, typically 11-15 days after the cells were injected. The average weight of the tumors in each treatment group for each cell line is calculated.
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/985,320 US5977134A (en) | 1996-12-05 | 1997-12-04 | Inhibitors of farnesyl-protein transferase |
PCT/US1998/025352 WO1999028313A1 (en) | 1996-12-05 | 1998-11-30 | Inhibitors of farnesyl-protein transferase |
US985320 | 2001-11-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1045843A1 true EP1045843A1 (en) | 2000-10-25 |
EP1045843A4 EP1045843A4 (en) | 2001-10-24 |
Family
ID=25531371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98960545A Withdrawn EP1045843A4 (en) | 1997-12-04 | 1998-11-30 | Inhibitors of farnesyl-protein transferase |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1045843A4 (en) |
AU (1) | AU1612099A (en) |
CA (1) | CA2312366A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0675112A1 (en) * | 1994-03-31 | 1995-10-04 | Bristol-Myers Squibb Company | Imidazole-containing inhibitors of farnesyl protein transferase |
WO1997036901A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036897A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036605A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036890A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036898A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
-
1998
- 1998-11-30 AU AU16120/99A patent/AU1612099A/en not_active Abandoned
- 1998-11-30 CA CA002312366A patent/CA2312366A1/en not_active Abandoned
- 1998-11-30 EP EP98960545A patent/EP1045843A4/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0675112A1 (en) * | 1994-03-31 | 1995-10-04 | Bristol-Myers Squibb Company | Imidazole-containing inhibitors of farnesyl protein transferase |
WO1997036901A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036897A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036605A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036890A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036898A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
Non-Patent Citations (1)
Title |
---|
See also references of WO9928313A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2312366A1 (en) | 1999-06-10 |
EP1045843A4 (en) | 2001-10-24 |
AU1612099A (en) | 1999-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5977134A (en) | Inhibitors of farnesyl-protein transferase | |
US6054466A (en) | Inhibitors of farnesyl-protein transferase | |
US6103723A (en) | Inhibitors of farnesyl-protein transferase | |
US5932590A (en) | Inhibitors of farnesyl-protein transferase | |
US6066738A (en) | Inhibitors of farnesyl-protein transferase | |
US6172076B1 (en) | Inhibitors of prenyl-protein transferase | |
US6090948A (en) | Inhibitors of farnesyl-protein transferase | |
EP1019391A1 (en) | Inhibitors of prenyl-protein transferase | |
US5968965A (en) | Inhibitors of farnesyl-protein transferase | |
AU3248600A (en) | Inhibitors of prenyl-protein transferases | |
WO1997036900A1 (en) | Inhibitors of farnesyl-protein transferase | |
US6015817A (en) | Inhibitors of farnesyl-protein transferase | |
US5972966A (en) | Inhibitors of farnesyl-protein transferase | |
AU704792B2 (en) | Inhibitors of farnesyl-protein transferase | |
AU3386600A (en) | Inhibitors of prenyl-protein transferase | |
AU1611199A (en) | Inhibitors of farnesyl-protein transferase | |
US6127390A (en) | Inhibitors of prenyl-protein transferase | |
WO1999020609A1 (en) | Inhibitors of farnesyl-protein transferase | |
EP1045843A1 (en) | Inhibitors of farnesyl-protein transferase | |
WO2000034239A2 (en) | Inhibitors of prenyl-protein transferase | |
WO2000075135A1 (en) | Biaryl inhibitors of prenyl-protein transferase | |
CA2305783A1 (en) | Inhibitors of prenyl-protein transferase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000704 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20000704;LT PAYMENT 20000704;LV PAYMENT 20000704;MK PAYMENT 20000704;RO PAYMENT 20000704;SI PAYMENT 20000704 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20010911 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07D 235/30 A, 7C 07D 471/04 B, 7C 07D 401/06 B, 7C 07D 403/06 B, 7A 61K 31/415 B, 7A 61K 31/47 B |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20011129 |